Browse Month: January 2018

NAPSRx – The National Association of Pharmaceutical Sales Representatives, pharmaceutical conferences.#Pharmaceutical #conferences

pharmaceutical conferences

Pharmaceutical conferences

Obtain Vocational Training For A Career In Pharmaceutical Sales Through The CNPR Pharmaceutical Sales Entry Level Program

Pharmaceutical knowledge is the basic building block in securing relationships with physician customers.

Pharmaceutical conferences

Utilize the FREE Pharmaceutical Sales Career Center

Post your resume and apply for open positions to expose it

to pharmaceutical companies.

Pharmaceutical conferences

Train For A Career in Pharmaceutical Sales. Enroll in the CNPR Entry Level Pharmaceutical Sales Program.

Aspiring pharmaceutical sales applicants should be familiar with clinical pharmacology, medical terminology, plus rules and regulations for selling pharmaceuticals to healthcare professionals.

Pharmaceutical conferences

Free 3 month trial for all current Pharmaceutical Sales Reps.

We would like to introduce you to the NAPSRX pharmaceutical sales rep association which has been servicing and working with industry reps since 2002. We look forward to assisting you so sign up today.

Pharmaceutical conferences

Pharmaceutical conferences

Pharmaceutical conferences

Pharmaceutical conferences

Pharmaceutical conferences

Pharmaceutical conferences

Pharmaceutical conferences

Pharmaceutical conferences

Pharmaceutical conferences





Merck pharmaceutical, merck pharmaceutical.#Merck #pharmaceutical

merck pharmaceutical

This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.





GMO Pharmacy: The Pervasiveness of GMOs in Medicines and Supplements, pharmaceutical grade supplements.#Pharmaceutical #grade #supplements

GMO Pharmacy: The Pervasiveness of GMOs in Medicines and Supplements

Pharmaceutical grade supplements

Pharmaceutical grade supplementsAlex Pietrowski, Staff Writer

The concern over eating genetically-modified foods is growing as more people learn about the harmful effects of genetically-modified organisms (GMOs). Although not readily publicized by the mainstream media, GMOs have been linked to various health complications such as tumors, organ failure, DNA damage, immune system disturbances, and infertility, among others. Simultaneously, GM contamination of conventional and organic foods is increasing.

The toxic hand of GMOs does not stop in our food supply. GMOs are used in various prescription medications and vaccines, and GMOs in vitamins and supplements is also common. There are numerous examples.

GMO methods are being used to create edible vaccines, as, for example, a way of incorporating swine flu virus into corn, allowing mass vaccinations. A large share of insulin medications is produced by genetic engineering. Companies are producing pharmaceutical proteins (including antibodies) in GM plants, as, for example, in the US, where rice has been engineered to produce the alpha-antitrypsin protein used to treat liver disease and hemorrhages.

This same process is being used in the production of additives and vitamins:

Genetically modified organisms are being used to produce flavors, binders, enzymes, food additives and vitamins. Genetic engineers identify an organism that produces a particular additive, then they genetically alter it. It is then placed in an incubator of sorts, where the organism grows and multiplies. After it has reached maximum growth, the vitamin is isolated and extracted. Source: www.hemphealer.com

Pharmaceutical grade supplementsToday, GMO corn is used in most major brands of vitamin C supplements. “Ninety-nine percent of the vitamin C used commercially in supplements in the U.S. is derived from genetically engineered corn.” (source: www.life-enhancement.com) GM soy derivatives are common in Vitamin E. Corn oil and/or soybean oil can be often found in gel-tablet supplements. GM wheat derivatives are also common in over-the-counter supplements. GMO ed food additives are added to all types of vitamin-fortified foods.

“GM microorganisms are used to make vitamin B2 (riboflavin), vitamin C (ascorbic acid), xanthan (a thickener), citric acid, and enzymes used in cheeses, breads and baked goods, alcoholic beverages, and juice.” Source: Organic Consumers Association

Although GMOs in vitamins and supplements are not revealed on labels, it is likely that most generic and brand-name supplements are, already, GMO products.

Fortunately, there are organic companies out there that are committed to offering GMO-free vitamins, such as NutriGold and NOW Foods. The Non-GMO Shopping Guide offers a comprehensive list of vitamins and supplements from companies enrolled in the Non-GMO Project Standard: nongmoshoppingguide.com

This article is offered under Creative Commons license. It’s okay to republish it anywhere as long as attribution bio is included and all links remain intact.

Help Waking Times to raise the vibration by sharing this article with the buttons below…





New pharmaceuticals, new pharmaceuticals.#New #pharmaceuticals

who we are

In 2008 Genesis Pharmaceuticals was founded by a group of physicians, pharmacists and entrepreneurs to be more than a business firm that aims at profit. Genesis was founded to be an influential organization in the Egyptian market and industry. It is a company with a unique orientation, a philosophy and a clear future vision.

New pharmaceuticals

corporate philosophy

New pharmaceuticals

New pharmaceuticals

New pharmaceuticals

divisions

New pharmaceuticals

Genesis has developed a broad network of business partners to support its endeavor to achieve its desired position in pharmaceutical market.

This network does not only include suppliers and manufacturers but importantly also include firms providing technical support in various fields such as

– Technology Transfer. – Product Formulation.

– Methods of Manufacture. – Methods of Analysis.

– Quality Assurance. – Material Analysis and Qualification.

And other business fields.

Technical support and technology transfer.

Emerson Resources Inc., USA.

A leading firm in providing technical support to pharmaceutical companies through numerous services such as Formulation Development, Analytical Method Development, Analysis and Testing, Staff Training, Raw Material Evaluation and Qualification, and other development and technology transfer activities.

Research and Development Genesis believes that research and development are the tools for improvement and the base for growth. That is why we cooperate with a number of local specialists to support us in these fields, both professionals and academics, through allied companies, universities, or research centers. The work of these research partners, and mutual cooperation, starts at the moment we think of having new products and not only is integrated into all the following processes, until market launch, but extends thereafter for measuring quality and testing efficiency in what is known as Postmarketing Studies.

From new port Oregon in the United States—west—to Shanghai, China—east—and from St. Petersburg in Russia—north—to Cape Town in South Africa—south—across the dour corners of the globe, Genesis is seeking cooperation with suppliers and contract manufacturers that are capable of providing high quality products in line with Genesis’ undertaken mission.

Integrating the available and brought-up knowledge with the long experience of reliable local manufacturers yields the most wanted fruits in producing high quality products with assured efficacy. Genesis is committed to work hand in hand with its contracted manufacturers in all processes formulation, production, and quality assurance to guarantee fulfillment of the required standards without any compromises.

4 Saudi Buildings Nozha St. – Heliopolis – Cairo – Egypt





Medical Jobs, Award Winning Medical Recruitment Agency Ireland, pharmaceutical rep job.#Pharmaceutical #rep #job

The Medical Jobs Recruitment Agency

Pharmaceutical rep job

Specialists in recruitment for Medical jobs in Ireland

Jackie Brown Medical Ltd is a specialist Irish Medical Recruitment Agency. We recruit across diverse sectors within the Medical jobs market in Ireland.

We work exclusively with medical, pharmaceutical and healthcare based Companies, Clinics and Hospitals.

Dedication in Recruitment

Our track record and word of mouth referrals conclusively show our absolute dedication to providing the best possible service to both job seekers and employers alike.

We are the recruitment specialists for medical jobs in Ireland

Pharmaceutical rep job

Jackie Brown RGN, NRF CertRP

Meet Jackie Brown

Jackie Brown is the proud owner of Jackie Brown Medical Ltd., an Irish owned medical recruitment agency (Est. 2007). Jackie has a reputation for honesty and integrity that has earned her the admiration of job seekers, client companies and a string of awards.

“Clients and Jobseekers must be treated with respect and transparency and it’s something our testimonials refer to regularly.”

Awards and Rewards

These include a Fellowship of the National Recruitment Federation, only awarded after 10 years of practice; Recruiter of the Year – Small Agency Award in 2008 and a holder of the only recruitment qualification in Ireland, the NRF Cert in Recruitment Practice. Currently Jackie is the one of the only people in Ireland with all three accolades.

Medical Background

As a registered general nurse Jackie is well placed to specialise in healthcare, science, pharmaceutical and medical recruitment.

Pharmaceutical rep job

Healthcare Jobs in Ulster, Munster, Leinster and Connaught. We’ve got Ireland covered.

With offices in both Co. Wicklow and Co. Wexford we recruit nationwide across Ireland. If you are looking for medical jobs or healthcare jobs in Galway, positions in Dublin or want to further your career in Cork, Kerry or Limerick, we would like to speak to you.

Diversity in a Speciality

We recruit a hugely diverse range of people within our medical speciality.

We have recruited Nurses, Doctors and Pharmacists. We have also found jobs for Social Workers, Radiographers and Project Managers. In a laboratory setting we have filled positions for Scientists QA’s. Medical Sales Representatives are a particular speciality at Jackie Brown Medical.

We are Irelands’ best Healthcare recruitment agency.

Pharmaceutical rep job

Medical Sales Specialists

Jackie Brown is Irelands leading Medical Sales Recruitment specialist. From early on in her career she has specialised in Medical Sales and Pharmaceutical Sales and has become not just a recognised Specialist in Medical Sales, but Irelands most respected Medical Sales Recruitment Consultant. Her in depth knowledge of Medical Sales and Pharmaceutical Sales has earned her the respect of Irelands top Sales Managers. This speciality has been championed throughout the company, and while Jackie remains the leading recruitment consultant for Medical Sales jobs in Ireland, she has educated the entire team because she is passionate about Medical Sales.

All our recruitment consultants have medical and/or HR backgrounds which means that every member of our team can understand your role and responsibilities. We speak your language.

Pharmaceutical rep job

National Recruitment Federation Membership (NRF)

Jackie Brown Medical Ltd is a member of the National Recruitment Federation of Ireland (NRF) which guarantees a professional service to our clients and candidates.

Recruitment Standards Advocates

At Jackie Brown Medical we are passionate about recruitment. We hold ourselves to extremely high standards. Education is crucial to our team. That’s what makes us a recruitment agency that companies love to work with. Our knowledge of the recruitment process and understanding of both jobseekers and clients needs put us at the top of our market.

We advocate recruitment standards at every opportunity. If you would like to know more about recruitment standards you should look at the advice on using recruitment agencies in our advice section, or simply pick up the phone and talk to us.

All the staff at Jackie Brown Medical recognise that a jobseeker is not simply looking for a job, and that a Client company is not just looking for an employee.

Pharmaceutical rep job

Job Advice and Resource Centre

Visit our Advice Centre. This is a compilation of information to assist you in getting the job you want.

Curriculum Vitaes (CV’s): How to make yours better in both layout and content,

Interview Tips: how to avoid common pitfalls,

Hover to pause or press the largest in the row of buttons to make the slideshow manual / start it again.

Testimonials

“” I would highly recommend Jackie Brown Medical recruitment agency as I myself got a job through this agency that I am very happy in! Jackie was so honest with me on the phone prior to my interview and gave me great advice! She also sent me a congratulations card upon being offered the job which I thought was extremely thoughtful of her and she keeps in touch with me frequently to see how things are going. “”

Dental Treatment Coordinator

“Jackie gets the deal going, with great assurance of heart from the start. Excellent interpersonal relationship ability, that you cannot help but go all the way with her in not only getting the job but staying on the job!”

Chief Resident Physician

“Very Positive! Staff are always helpful and obliging. Got back to me very quickly regarding interviews and offer letters. Jackie Brown kept me up to date with all the details leading up to my offer and acceptance. Many thanks to her for a great service.”

Business Development Manager

“I have found Jackie and the team to be an excellent recruitment partner and working together we have sourced some excellent talent to our business. They know what we look for and do not waste time sending you candidates that are not at the right levels of skills and experience. Jackie Brown Medical excel with a great personal approach to recruitment – a great recruitment partner. “

Human Resources Manager

“”I have worked with Jackie Brown Medical for a number of years now both as an employer and as a candidate. I consider Jackie to be my No.1 recruiter because she always takes the extra time needed to make sure that she not only understands the key requirements of the role but more importantly what type of personality will best fit the organisation. This ensures that the candidates always hit the mark and stand out from the crowd. Jackie and her staff all have a great understanding of the medical industry and I have also found them a great source of guidance when planning my recruitment strategies. Jackie is a thorough professional and I couldn’t recommend her strongly enough.”





Exclusive: White House task force echoes pharma proposals, pharmaceutical prices.#Pharmaceutical #prices

Exclusive: White House task force echoes pharma proposals

By Emily Kopp, Kaiser Health News

Pharmaceutical prices

President Trump is expected to issue an executive order on drug pricing soon. A Kaiser Health News investigation reveals pharma’s effort to influence that order. John Minchillo/AP

resident Donald Trump repeatedly talks tough about reining in the pharmaceutical industry, but his administration’s efforts to lower drug prices are shrouded in secrecy.

Senior administrative officials met Friday to discuss an executive order on the cost of pharmaceuticals, a roundtable informed by Trump’s “Drug Pricing and Innovation Working Group.” Kaiser Health News examined documents that shed light on the workings of this working group.

The documents reveal behind-the-scenes discussions influenced by the pharmaceutical industry. Joe Grogan, associate director of health programs for the Office of Management and Budget (OMB), has led the group. Until March, Grogan served as a lobbyist for Gilead Sciences, the pharmaceutical company that priced its hepatitis C drugs at $1,000 per pill.

To solve the crisis of high drug prices, the group discussed strengthening the monopoly rights of pharmaceuticals overseas, ending discounts for low-income hospitals and accelerating drug approvals by the Food and Drug Administration. The White House declined to comment on the working group.

The group initially met May 4 in the Eisenhower Executive Office Building and has since met every two weeks. In addition to OMB, the working group includes officials from the White House National Economic Council, Domestic Policy Council, Health and Human Services, the FDA, the Federal Trade Commission, the Department of Commerce, the Office of the U.S. Trade Representative and the Department of Justice.

According to the documents — the latest of which is dated June 1— the working group focused on the following “principles” and “talking points”:

  1. Extending the patent life of drugs in foreign markets to “provide for protection and enforcement of intellectual property rights.” This will ensure “that American consumers do not unfairly subsidize research and development for people throughout the globe.”

Extending monopoly protections for drugs overseas has been one of the pharmaceutical industry’s top priorities since the Trans-Pacific Partnership was defeated last year.

That policy would push up global drug prices, according to Médecins Sans Frontières.

  1. Promoting competition in the U.S. drug market — both by “modernizing our regulatory and reimbursement systems” and limiting “barrier to entry, including the cost of research and development,” according to the documents.

The working group also discussed two broad policy ideas that have been championed by the pharmaceutical industry, according to sources familiar with the process:

  1. Value-based pricing, when pharmaceutical companies keep the list prices of drugs unchanged but offer rebates if patients don’t improve. It’s unclear who would audit the effectiveness of the drugs, what criteria they would use to evaluate them and who would receive the rebates. Grogan invited Robert Shapiro — an adviser for Gilead and former secretary of Commerce under President Bill Clinton — to brief the working group on value-based pricing on May 18. Shapiro is the chairman and co-founder of Sonecon LLC, a Washington, D.C., firm that consulted with Gilead, Amgen and PhRMA, according to his curriculum vitae.
  1. Grogan and Shapiro also discussed issuing 10-year U.S. Treasury bonds to drug manufacturers to pay for expensive, hepatitis C drugs like Sovaldi and Harvoni under Medicare and Medicaid, to avoid rationing drugs to the sickest patients. The 2015 Senate investigation, for example, found that though Medicaid spent more than $1 billion on Sovaldi, just 2.4 percent of Medicaid patients with hepatitis C were treated.

After the working group’s first meeting on May 4, Grogan distributed detailed policy recommendations on expediting generic drug approvals, creating a new tax credit “of up to 50 percent” for investments in generic drug manufacturing, distribution and research and development. The documents also propose scaling back the 340B program, which requires drug manufacturers to provide some medicines at a discount to hospitals that treat low-income patients.

Most of these policies would not ease patient costs, and at least one would increase prices, say experts who reviewed the documents at the request of Kaiser Health News.

“This six-page document contains the kind of solutions to the cost-of-drugs problem that you would get if you gathered together all the executives of pharma and asked them ‘What sort of token gestures can we do?’ ” said Vinay Prasad, a professor of medicine at Oregon Health and Sciences University who studies the costs of cancer drugs.

The pharma-friendly recommendations appear to clash with earlier press reports indicating that OMB Director Mick Mulvaney was considering requiring drugmakers to pay rebates to Medicare patients, a measure the pharmaceutical lobby fiercely opposes.

Brand-name drug prices — which account for 72 percent of drug spending — go untouched in the handouts, said Fiona Scott Morton, a Yale economics professor and former attorney with the Justice Department’s antitrust division.

“The changes to generic markets to promote competition look helpful, but there need to be some more ideas to create more competition for branded drugs or consumers aren’t really going to notice this,” Scott Morton said.

Some of the text in the document is cribbed directly from policy papers published by the pharmaceutical industry’s powerful lobby — Pharmaceutical Research and Manufacturers Association (PhRMA).

Under the subtitle, “Encourage Use of 21st Century Tools for Drug Evaluation, Review and Approval,” one handout proposes the FDA use less rigorous clinical trial standards to speed drug approvals.

The handout cites a PhRMA paper from March 2016 that includes an identical subtitle, “Encourage Use of 21st Century Tools for Drug Evaluation, Review and Approval,” and recommends the FDA implement less rigorous clinical trial standards.

These recommendations would not lower drug prices, experts say.

Such measures “would be like a firefighter spraying gasoline on your burning garage,” Prasad said.

Another section — which recommends giving the FDA more discretion to evaluate generic copies of complex drugs — closely resembles a National Law Review article written by two lobbyists in the pharmaceutical division of Foley Lardner, whose clients include generic drugmakers.

The handouts further recommend allowing drugmakers to supply data and off-label information to insurers and pharmacy benefit managers during the clinical trial period, before they secure FDA approval.

That’s a “terrible idea,” said Jerry Avorn, a professor at Harvard Medical School and the chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. “That’s why we have the whole approval process, to determine what’s actually true,” he said.





IT Staffing Solutions – The Computer Merchant, pharmaceutical staffing agencies.#Pharmaceutical #staffing #agencies

Technology Staffing

The Computer Merchant, Ltd. (TCM) has been deploying top-notch IT talent for our clients in 48 states across many diverse industries and cutting-edge technologies since 1980. What can we do for you?

Pharmaceutical staffing agencies

Big Data, Analytics Cyber Security

The Computer Merchant’s Big Data, Analytics & Cyber Security team can help your organization capture and transform data into competitive advantage.

Pharmaceutical staffing agencies

Banking Finance Services

TCM has been powering the US Banking & Financial Services sector for over three decades with thousands of specialized IT professionals deployed on critical technology initiatives across the Banking, Finance, Private Wealth Management and Insurance arenas.

Pharmaceutical staffing agencies

Healthcare Services

With 30+ years of healthcare market experience, we understand the pressure your clients are under to meet legislative deadlines such as HIPAA, ACA, ICD-10 and EHR meaningful use. We know they must reduce skyrocketing healthcare costs and drive innovation across their core healthcare delivery systems.

Pharmaceutical staffing agencies

Life Sciences Services

With over two decades of IT staffing experience in the pharmaceutical and biotechnology industries, we understand the pressure to meet regulatory and compliance directives while driving innovation and profitability. We can help.

Pharmaceutical staffing agencies

Government Services

The Computer Merchant has deployed thousands of IT consultants across more than 30 federal agencies. We have a 35 year track record of powering Global 1000 clients and are annually ranked by the Boston Business Journal among the Area’s Largest IT Staffing Firms.





Staffing Plus – A Premier Healthcare Staffing Firm, pharmaceutical staffing agencies.#Pharmaceutical #staffing #agencies

Job Seekers

Learn why Behavioral Health, Allied Health, Nursing, HR and Pharmacy professionals turn to Staffing Plus to find their best career opportunities.

Clients

From Temporary, Per Diem, Temp-to-Hire and Permanent staffing to innovative HR services, Staffing Plus has the talent and expertise you need to make your organization soar.

Behavioral Health & Education

Staffing Plus works with the top providers of behavioral health services in the region.

Pharmaceutical staffing agencies

Allied Health

Staffing Plus’ management and staff collectively have over 56 years of Allied Health staffing experience and relationships.

Pharmaceutical staffing agencies

Nursing

We are dedicated to staffing qualified Nurses for per diem, temp-to-perm, contract direct hire positions.

Pharmaceutical staffing agencies

Pharmacy

At Staffing Plus, we go the extra mile to match qualified pharmacy professionals with healthcare and pharmaceutical companies.

Pharmaceutical staffing agencies

Government Services

Staffing Plus provides a broad range of experienced healthcare and administrative professionals to Federal Government agencies.

Pharmaceutical staffing agencies

HR Solutions

At Staffing Plus we understand that managing the global functions of HR can be a challenge. That is where we come into play.

Pharmaceutical staffing agencies

Referral Program

We understand that you have many choices when working with a staffing firm and we appreciate your continued loyalty.

Pharmaceutical staffing agencies

Pharmaceutical staffing agencies





Medzilla; Biotech Jobs, Pharmaceutical Jobs, Pharmaceutical Sales Jobs, Resumes, Medical Career, Job Board, Biopharmaceutical Jobs,

MedZilla

  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies

  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies
  • Biopharmaceutical companies

This Week’s Featured Jobs

Opportunity posted by Sunrise Systems Inc

Opportunity posted by Lexicon Pharmaceuticals

Opportunity posted by The Medical Affairs Company

Opportunity posted by Lexicon Pharmaceuticals

Opportunity posted by Takeda Pharmaceuticals

Opportunity posted by PDI, Inc

Opportunity posted by Novartis

Opportunity posted by Touchpoint Solutions

Opportunity posted by Lundbeck

Opportunity posted by inVentiv Health

View our Newest Jobs by State

View our Newest Jobs by Profession

Employers & Recruiters

Search now, thank us later:

Search our pre-screened candidates for the talents you need now for FREE!

– Mark S, Sales Executive

– James D, Lab Technichian

– T. Baker, University of Florida

– K. Dalton, Clinical Director

– S. Ohlinger, Pharmaceutical Sales Rep

– Thom B, ETS Systems

Job Seekers

Post your resume to become Medzilla Certified and start getting job offers NOW!

Post your Resume

Hot Topics on Our Forums

ICON offers up to 7K per calendar year for tuition reimbursement. Eligibility begins the 1st of the following month after date of hire.

Just wonder what CRO provide tuition reimbursement or yearly allowance for school. I am not asking about PMP or ACRP fees for exams etc. This would be for some one that wants to get their MBA, law degree etc.

Looking for advice from those who are in pharma Sales or recruit for pharma sales. I have always been interested in sales and at the same time I was applying to graduate schools for my teaching certificate, I was also applying to pharma. companies . Read More

Latest Articles

The MedZilla.com Employment Report: Permanent R ?>

SRS Pharmaceuticals Pvt, pharmaceutical prices.#Pharmaceutical #prices

pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Pharmaceutical prices

Our products are available to local pharmaceutical distributors in most countries.

Pharmaceutical prices

Pharmaceutical prices

Our products are available under private label to our distributors and partners.

Pharmaceutical prices

Pharmaceutical prices

We work with our distributors, strategically programmatically, to accelerate, expand extend the product life cycles of ethical drugs.

Pharmaceutical prices

Pharmaceutical prices

We can provide, clinical Trials, FDA Certificates and BE Studies for registration of our products as per guidelines of most health authorities in most countries.





Top 15 US Pharmaceutical Companies In 2016-2017, generic pharmaceutical companies.#Generic #pharmaceutical #companies

Top 15 US Pharmaceutical Companies By 2016 Revenues

90% of the industry’s total market share, and

100% of the industry’s profit.

Generic pharmaceutical companies

Top 15 US Pharmaceutical Companies By 2016 Revenues

Johnson Johnson ranked No. 1 in R P Top 15 US Pharmaceutical Companies list, is a holding company. The Company and its subsidiaries are engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates through three segments: Consumer, Pharmaceutical and Medical Devices.

Pfizer Inc., ranked No. 2 in R P Top 15 US Pharmaceutical Companies list, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Merck Co., ranked No. 3 in R P Top 15 US Pharmaceutical Companies list, is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances.

Gilead Sciences ranked No. 4 in R P Top 15 US Pharmaceutical Companies list, is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. Its products include AmBisome, Atripla, Cayston, Complera/Eviplera, Descovy, Emtriva, Epclusa, Genvoya, Harvoni, Hepsera, Letairis, Odefsey, Ranexa, Sovaldi, Stribild, Truvada, Tybost, Vemlidy, Viread, Vitekta and Zydelig. The Company’s areas of focus include HIV; liver diseases, such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection; hematology/oncology; cardiovascular, and inflammation/respiratory diseases.

AbbVie Inc. ranked No. 5 in R P Top 15 US Pharmaceutical Companies list is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.

Amgen Inc. ranked No. 6 in R P Top 15 US Pharmaceutical Companies list, is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company operates in the human therapeutics segment. The Company’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Eli Lilly and Company ranked No. 7 in R P Top 15 US Pharmaceutical Companies list, is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals.

Abbott Laboratories ranked No. 8 in R P Top 15 US Pharmaceutical Companies list, is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Company, through St. Jude Medical, Inc., also offers a range of products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Bristol-Myers Squibb Company ranked No. 9 in R P Top 15 US Pharmaceutical Companies list, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically-synthesized drugs, or small molecules, and products produced from biological processes called biologics. The Company’s products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise.

Allergan plc ranked No. 10 in R P Top 15 US Pharmaceutical Companies list, is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand-name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine, and International.

Biogen Inc. ranked No. 11 in R P Top 15 US Pharmaceutical Companies list, is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Shire plc ranked No. 12 in R P Top 15 US Pharmaceutical Companies list, is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Celgene Corporation ranked No. 13 in R P Top 15 US Pharmaceutical Companies list, is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuroinflammation.

Mylan N.V. ranked No. 14 in R P Top 15 US Pharmaceutical Companies list, is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand-name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World.

Valeant Pharmaceuticals International, Inc., ranked No. 15 in R P Top 15 US Pharmaceutical Companies list, is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). The Company operates through two segments: Developed Markets and Emerging Markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products, and medical devices.

The rankings of the top 15 pharmaceutical companies in the US have been compiled from R P US Top 3000 database – R P Screener. For comments, suggestions contact @pharavi





BioPlan Associates – Biopharmaceutical Manufacturing Capacity – Production, biopharmaceutical companies.#Biopharmaceutical #companies

Biopharmaceutical companies

Biopharmaceutical companies

The 2016 13th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most recent study of biotherapeutic developers and contract manufacturing organizations’ current and projected future capacity and production.

Published by BioPlan Associates, Inc. April 2016

Biopharmaceutical companies

Biopharmaceutical companies

Biopharmaceutical companies Biopharmaceutical companiesBiopharmaceutical companies

  • Coverage
  • Table of Contents
  • By the Numbers

This report’s 468 pages of data-rich analysis will help improve your decision-making in biomanufacturing operations, with in-depth analysis of capacity, production trends, benchmarks, and much more:

  • Biosimilars pipeline in development
  • In-depth analysis of key data, capacity, production trends, and benchmarks
  • Budget trends and impact of current economic environment
  • Expression system advances
  • Downstream purification problems and issues
  • Current and projected industry bottlenecks
  • Capacity utilization and current production levels
  • How capacity bottlenecks are being resolved
  • Production trends and implications for industry
  • Outsourcing trends
  • International offshoring through 2017
  • Range of titres, growth
  • Disposables: Spending growth; downstream uses; L reasons for increasing/ restricting; budget increases; vendor satisfaction
  • Disposables: Compare innovators vs CMOs & US vs Europe
  • Batch failure rates & trends
  • Selecting a CMO Problems & solutions
  • Quality management & PAT implementation
  • Hiring and employment growth
  • Supplier growth rates
  • Much more.

Compare 238 biotherapeutic developers vs CMOs; US vs European & Global Biomanufacturing





University of Veterinary and Pharmaceutical Sciences Brno, pharmaceutical index.#Pharmaceutical #index

UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES BRNO

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

Pharmaceutical index

University of Veterinary and Pharmaceutical Sciences Brno

  • a public university with more than 90 years of tradition
  • interesting and promising study programmes in the areas of Veterinary Medicine, Veterinary Hygiene and Ecology, and Pharmacy, taught in Czech and English
  • concentrated in a university campus near the centre of the city
  • the best of traditions combined with modern teaching methods and excellent equipment

Palackeho tr. 1946/1, 612 42 Brno, Czech republic

The University of Veterinary and Pharmaceutical Sciences Brno was founded in 1918. At the moment the university consists of three faculties – Faculty of Veterinary Medicine, Faculty of Veterinary Hygiene and Ecology, and Faculty of Pharmacy. The VFU Brno is the only university in the Czech Republic specializing in veterinary medicine, veterinary hygiene and ecology, and just one of two teaching pharmaceutical science. It is found within the City of Brno in the city district of Brno – Královo Pole, in the university campus, where all educational and research facilities are located.





Biofarms – to Integrate Vaccines, Drugs into – Biopharmaceutical – Crops, Natural Society, biopharmaceutical companies.#Biopharmaceutical

biopharmaceutical companies

Biopharmaceutical companies

Biopharmaceutical companies

Biofarms to Integrate Vaccines, Pharmaceuticals into GMO Biopharmaceutical Crops

Biopharmaceutical companies

Posted on October 8, 2012

Biopharmaceutical companiesThe truth really is much stranger than fiction, especially when it comes to the open and admitted future plans of major biotechnology companies. One such case involves a biotech company known as ProdiGene, the officials from which actually faced jail time back in 2002 for contaminating the traditional food supply with biopharmaceutical crops that were growing pharmaceuticals and vaccine components associated with AIDS, diabetes, and diarrhea.

Contaminating 500,000 bushels of soy with their biopharmaceutical corn that contained pharmaceutical and vaccine components associated with deadly diseases, the company was slapped with a minor $500,000 fine by the USDA (the same government organization that gives Monsanto s crops special speed approval and ignores the company s blatant disregard for its regulations). As it turns out, the pharmaceutical crops were actually mixed in with traditional crops and unknowing farmers had already been planted for human consumption. The USDA claims, however, that the crops were confiscated.

After receiving the fine and some press coverage on the subject, ProdiGene decided not to apologize but to expand their mission. The company, in combination with estimates by Dow AgroSciences, stated that they sought to reach $200 billion in biopharmaceutical crops within 10 years (as of 2004). Furthermore, they estimated that 10% of the corn in the United States will be biopharmaceutical in nature.

In other words, it could contain hidden nano-scale vaccinations, antibiotics, anti-depressants, or any form of pharmaceutical drug. One California based company has even created a spermicidal corn to be used as a mass contraceptive. In an AlterNet piece covering the issue entitled Spermicidal Breakfast Cereal , author Carmelo Ruiz-Marrero asks:

What would happen if contraceptive corn or antibiotic wheat accidentally made it to the supermarket? Nobody knows, but that isn t stopping agribusiness from pursuing these crops.

Vaccines, Drugs, Sterilizations to be Fused into Nation s Dinner?

The existence of such technology brings the fight against GMOs to an entirely new level. Outside of the known effects such as recent links to tumors, DNA damage, and other complications, GMO crops on your dinner table could soon contain pharmaceutical drugs like statins in an effort of mass medicating the public. Such an effort would likely be used in conjunction with others to fight against those who choose to opt out of vaccinations, delivering the vaccine through the food supply.

It may sound absurd, and it is, but is not a new notion. Researchers previously designed a method in which mosquitoes could be flying vaccine carriers to inject large numbers of individuals with vaccinations without their knowledge of consent. As one spokesman for a major ecology organization explained:

One single mistake from a biotechnology company and we ll be having someone else s prescription medicine for breakfast in our cereal, explained Larry Bohlen from Friends of the Earth, an international ecology organization.

The information ties in with the recent news revealing that Monsanto now owns a monumental gene silencing technology for pharmaceutical use in humans. The king biotechnology company even forged a recent alliance with Alnylam Pharmaceuticals, Inc. to get the initiative started. After all, Monsanto would not lose an opportunity to conquer a large portion of the massive $200 billion biopharmaceutical crop market.

Other corporations are looking to get a chunk too, with the molecularfarming.com website acting a hub for farmers willing to lease their land for biopharmaceutical experiments across the globe. Touting a net worth of $80 billion in the coming years, investors are continually looking to get their hands on biopharmaceutical growing operations to churn out drug-containing GMO crops for mass consumption and mass profits. So far, they ve garnered contracts as far as Zimbabwe to continue their operations.

Just like regular GMOs, DDT, and cigarettes, experts are concerned that the real effects of biopharmaceutical growth may not be recognized until decades later.

What will have to happen before the Department of Agriculture takes seriously the fact that millions of people almost ended up consuming experimental drugs and chemicals? asks Brandon Keim, of the Council for Responsible Genetics in reference to the ProdiGene scandal. A few sensational deaths? Maybe an increase in debilitating disorders which will only be noticeable some decades later, when it s already too late?

If the public grows more aware of GMO dangers with the grassroots support and potential passing of Prop 37, however, biopharmaceutical farms may never see mainstream success.

Biopharmaceutical companies

Biopharmaceutical companies

Anthony is a natural health and human empowerment writer, speaker, and entrepreneur whose writings have appeared in #1 USA Today and Wall Street Journal Best-Selling books and top 100 websites. After overcoming Lyme Disease and nerve-related facial paralysis, Anthony’s work now reaches several million readers per month through his highly prolific group of social media pages and websites. Focused on self-development techniques and living a healthy lifestyle, Anthony currently sits on the Advisory Board to Natural Society in addition to managing and directing several other companies dedicated to enhancing social good. Anthony’s work routinely appears on both alternative and established websites and television programs alike, including Drudge Report, Thom Hartmann, Simple Reminders, RT, Infowars, Michael Savage, Gaiam TV, and many others.





Medical, Pharmaceutical, Medication Packaging: Medical Packaging Inc, pharmaceutical labeling.#Pharmaceutical #labeling

Unit-Dose Medication Packaging Solutions

Delivering a full range of quality unit-dose medication packaging equipment and materials

Customized for a Range of Market Segments

Serving the unique needs of pharmacies, hospitals, extended care facilities, and many others

A Global Leader in Pharmaceutical Packaging

Providing unmatched quality and service to customers worldwide for over four decades

Contact Us Today to Discuss Your Requirements

Rely on our courteous experts for solutions to your packaging and labeling challenges

Welcome to Medical Packaging Inc.

Complete Medication Packaging Solutions

Pharmaceutical labeling

Medical Packaging Inc. (MPI) is a leading global manufacturer of unit-dose medication and pharmaceutical packaging and labeling systems, equipment, barcode labeling software, and MPI-certified consumable materials. Since 1971, MPI has been providing top-quality products, custom-tailored medical packaging solutions, and outstanding service to customers worldwide. At MPI, we are proud to meet the needs of medication packagers in a variety of market segments, from independent pharmacies to long-term care facilities, hospitals, and many others.

Ready to Learn More About Us?

Markets and Care Settings

Pharmaceutical labeling

Hospitals and Acute Care

Our unit-dose medication packaging and labeling systems for hospitals and acute care facilities are carefully tailored to each customer s unique needs. Meeting a full range of pharmaceutical packaging requirements, our medication packaging machines and materials are premium quality and our products are available individually, in bundles, or as a complete, customized solution to meet virtually any requirements.

Pharmaceutical labeling

Extended Care Pharmacies

We offer unit-dose medication packaging and labeling systems which are uniquely suited to packaging oral solid and oral liquid medications in seven-day or less cycles in extended care (EC) and long-term care (LTC) pharmacies. Our medicine packaging and labeling machines and materials are perfect for maintaining compliance with the CMS-mandated short-cycle dispensing model in LTC/EC pharmacy environments.

Pharmaceutical labeling

Small Pharma

MPI serves small pharmaceutical manufacturers and contract drug manufacturing organizations with liquid cup unit-dose packaging systems that are capable of delivering high-quality, FDA-compliant packages at a low price point with an easy-to-use design. Our medicine packaging solutions for small pharma customers are perfect for lower-volume products that cannot be run profitably on high-speed packaging lines.





Find Pharmaceutical Jobs In Ireland, pharmaceutical manufacturing jobs.#Pharmaceutical #manufacturing #jobs

Pharmaceutical Jobs

Pharmaceutical manufacturing jobs

WE ARE EXPANDING OUR TEAM

EirGen Pharma is expanding and adding a second site locally in Waterford, as part of this growth we have a number of key positions which all come with a competitive salary and benefits package as well as opportunity to join an exciting global pharmaceutical company.

To apply for any of the roles listed, or to obtain further information, email us at [email protected].

When applying for any of these positions, please include your CV, a Covering Letter and clearly state for which Job Position you are applying.







EirGen Job Opportunities

Please click below for a recent advertisement which we recorded showcasing the opportunities that are currently open to interested candidates:

In the event that the below links do not grant you access to apply, please forward your application to [email protected] mentioning the relevant position in your title.

R D ANALYTICAL DEVELOPMENT CHEMIST

  • Working in EirGen’s new state of the art, purpose built R D facility!
  • Developing, transferring and validating robust, sound analytical methods
  • Using your problem solving skills to troubleshoot methods
  • Analysing all raw materials, in process samples and finished products in a timely and efficient manner to ensure quality and efficacy of the product
  • Taking part in laboratory investigations
  • Attending internal project review meetings as required
  • Assisting in the preparation for customer/ regulatory inspections
  • Preparing submission documentation in support of license applications
  • You MUST be passionate about R D
  • A degree in Chemistry (or a related science discipline)
  • You MUST have at least 3+ years’ pharma lab based experience
  • Appreciate the importance of following SOPs and good GDP/GLP
  • Enjoy technical report writing
  • Self-starter who enjoys working in a fast paced environment
  • You MUST enjoy working as part of a team and be fun and friendly

Earn extra credit by meeting the following criteria:

  • Have experience in method development/transfer/validation
  • Be proficient in HPLC and Empower 3 Software
  • We have an active Sports and Social Club and they organise all sorts of fun events from trips to the cinema, to cycling the Greenway, to climbing the Wibit in Dunmore and everything else in between!
  • Let them eat cake we say! Any excuse for cake and we’re on it
  • We like healthy stuff too, sometimes we even have salads with our Free Food Friday lunches
  • We host all sorts of fun events to help raise money for our employee chosen charities – this even includes doing a spinning class!

What will you get if you work with us?

Aside from having a great day at work, you’ll also get:

  • A great work environment with lots of fun
  • A chance to work with like-minded people
  • Be part of a team of people who work together to make life-saving products
  • Work in Ireland’s Pharma Company (SME) of the Year
  • A great financial package to meet your knowledge and experience
  • A company contributed pension
  • Health Insurance
  • Extra day’s holidays
  • Company sponsored events and nights out
  • And lots of other stuff!!

We are a rapidly growing pharmaceutical company and we need more great people to join our team to keep growing at this speed! We pride ourselves in recruiting, developing, and retaining the best people.





10 Facts about the U, pharmaceutical containers.#Pharmaceutical #containers

First American Plastic

Pharmaceutical containers

As far as American manufacturing goes, the plastics sector is among the most notable success stories, helping to lead the way in economic recovery. Injection molding remains a vital part of the U.S. economy and a source for hundreds of thousands of jobs. Below are 10 facts that show the continued success of the injection mold industry based on data compiled by the Plastic Industry Trade Association, the American Chemistry Council and the U.S. Bureau of Labor Statistics.

1. In the United States, the plastics industry is the third-largest manufacturing industry. And the outlook is strong, with everything from injection molding companies to 3D printing in high demand around the world.

2. The plastics industry isn’t just massive — it actually translates to jobs. The industry employs nearly 900,000 workers in the United States alone, making plastics a key building block within manufacturing and for the U.S. job force overall. And that’s just part of the story — when you include plastics suppliers the number goes even higher, with the entire plastics industry accounting for roughly 1.4 million jobs nationally.

3. Injection molding and plastic manufacturing facilities can be found throughout the country in all 50 states. In fact, there are nearly 16,000 facilities just in the United States.

4. It’s a multi-billion dollar industry. In 2012, plastics manufacturers shipped about $373 billion in goods.

5. In an encouraging sign that plastics manufacturers are optimistic about their industry, they spent upwards of $10 billion in 2012 on new capital equipment.

6. It’s worth the investment. Already, plastics manufacturers are enjoying a surge in activity on the consumer side. In fact, consumption of plastic products went up 5.7 percent between 2011 and 2012.

7. The success of American plastic manufacturing depends in part on global interest; the world relies on U.S. plastic manufacturing. The top three countries that benefit from American plastics by way of U.S. exports are Mexico, Canada and China.

8. It’s no secret that manufacturing as a whole has taken a beating in recent decades — especially during the most recent recession — but plastics is among the sectors that are actually growing. In the last 25 years, manufacturing has dropped an average of 1.4 percent each year, while plastics manufacturing has increased at an average annual rate of 0.1 percent.

9. When compared with manufacturing as a whole, the plastics industry actually enjoys a sizable trade surplus, logging $13.1 billion in 2012.

10. How much actual plastic does this translate into? The answer: tons and tons. Roughly 107.5 billion pounds of plastics and resins were manufactured in 2013 — an increase over the previous year’s 105.9 billion pounds.





Pharmaceutical Companies of Johnson & Johnson, Janssen, new pharmaceutical companies 2013.#New #pharmaceutical #companies #2013

new pharmaceutical companies 2013

We engage in approximately 400 active collaborations — from discovery to late-stage development — with academia, pharmaceutical and biotech peers, and other public- and private-sector partners.

Partner With Us

Together, we can solve problems

and find transformational solutions.

We believe that partnerships are essential to drive change, innovation and transformation, and we are committed to ensuring the success of our collaborations.

New pharmaceutical companies 2013

Betsy Gross

Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses.

New pharmaceutical companies 2013

Cliff Enright

Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses. Learn more about Cliff’s story, “A Colorful Life”.

New pharmaceutical companies 2013

Dennis Owen Frohlich

Green Tree Repaint

Diagnosed with ulcerative colitis in 2007, Dennis created an educational website to share his story. Today, his academic career focuses on health communication and exploring the internet’s role in promoting health and well-being.

New pharmaceutical companies 2013

Dorethey Gorham

Day Of The Armada

Dorethey is a joyful, self-taught artist living with arthritis, general anxiety syndrome and diabetes.

New pharmaceutical companies 2013

Jane Kielt

A retired art teacher and world traveler, Jane has had a passion for art since childhood. Through painting watercolors, she finds inspiration and healing throughout her experience living with multiple myeloma. Learn more about Jane by reading her story “The Art of Getting Lost.”

New pharmaceutical companies 2013

Jennifer Jacobs Baruch

Jennifer is a New York–based artist living with type 1 diabetes.

New pharmaceutical companies 2013

Melinda

Melinda’s artwork reflects her journey living with HIV.

New pharmaceutical companies 2013

Rhonda Fenwick

Through her art, Rhonda has explored psoriasis, a chronic skin disorder she has lived with since the age of six.

New pharmaceutical companies 2013

Robert Wright

Artwork from the National Art Exhibitions of the Mentally Ill, Inc. (NAEMI), an organization dedicated to discovering and preserving the art of people with mental illness.

New pharmaceutical companies 2013

New pharmaceutical companies 2013

Betsy Gross

Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses.

Tap here to expand

New pharmaceutical companies 2013

New pharmaceutical companies 2013

Cliff Enright

Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses. Learn more about Cliff’s story, “A Colorful Life”.

Tap here to expand

New pharmaceutical companies 2013

New pharmaceutical companies 2013

Dennis Owen Frohlich

Green Tree Repaint

Diagnosed with ulcerative colitis in 2007, Dennis created an educational website to share his story. Today, his academic career focuses on health communication and exploring the internet’s role in promoting health and well-being.

Tap here to expand

New pharmaceutical companies 2013

New pharmaceutical companies 2013

Dorethey Gorham

Day Of The Armada

Dorethey is a joyful, self-taught artist living with arthritis, general anxiety syndrome and diabetes.

Tap here to expand

New pharmaceutical companies 2013

New pharmaceutical companies 2013

Jane Kielt

A retired art teacher and world traveler, Jane has had a passion for art since childhood. Through painting watercolors, she finds inspiration and healing throughout her experience living with multiple myeloma. Learn more about Jane by reading her story “The Art of Getting Lost.”





Pharm Exec s Top 50 Companies 2016, Pharmaceutical Executive, generic pharmaceutical companies.#Generic #pharmaceutical #companies

generic pharmaceutical companies

T hough the companies represented in the top 50 of global sales leaders have remained remarkably stable over time, their relative positioning within the list continues to shift. This reflects the importance that product launches and innovative campaigns to grow existing medications at every stage of the product life cycle now play in building a sales advantage against truly brutal levels of competition. It helps explain why Pfizer resumes its position this year as the industry s prescription sales leader, displacing Novartis in the No. 1 ranking by widening its therapeutic franchise in vaccines a segment that Novartis recently abandoned with a strong performance for its multi-indication pneumoccocal preventive, Prevnar 13.

Further down the list, we also find signs of a pause in the once heady ascent of what Pharm Exec calls the stealth players: middle-rank companies with records of product innovation and new-age marketing that could propel them to the top 10. So far, only one of the stealths has accomplished that feat: Gilead Sciences, which two years ago leaped from 25th place to 9th last year, with its breakthrough hepatitis C cure breaking all sales records. But, in another sign of the relentless pressure to perform above expectations, Wall Street now says Generic pharmaceutical companiesit s time for an encore; without one, the company s continued place on the pole posting of privilege is not guaranteed.

Likewise, the entry of a generic player to the top ranks is still an object on the horizon. Despite the certainty of a larger portfolio as Teva acquires Allergan s generics business, its move to the top 10 is contingent on bucking the threat that price deflation, launch delays, other regulatory challenges and dwindling LOE opportunities pose to the generic sector s overall bottom line.

Ultimately, it s all about the quality and scale of the product franchise and how effectively that franchise is managed and executed across every element of the biopharma operations playbook.

That s why a special feature accompanying this year s Pharma 50 list highlights what we at Pharm Exec continue to insist is the value hidden in a company s human assets. In what is now a global war for talent, commitment to diversity and inclusion in human capital is an across-the-board competitive differentiator.

Our guest authors at the executive recruitment and talent management firm Russell Reynolds Associates put it succinctly: Diversity is the hardware that brings different machines together. Inclusion is the software that brings the system to life. Well said and a call to action for every biopharma company who has a place in our Pharma 50 or aspires to it.

See how the top 50 biopharma revenue generators stack up below (click on the tables to enlarge). The rankings also include each company’s top-selling products in 2015 and their total R D investment for the year. Pharm Exec would like to acknowledge the contributions of market intelligence firm Evaluate Ltd for once again providing the data for our annual feature. For details on how the listings were compiled, see the explainer below.

Generic pharmaceutical companies Generic pharmaceutical companies Generic pharmaceutical companies Generic pharmaceutical companies Generic pharmaceutical companies





SRS Pharmaceuticals Pvt, pharmaceutical drug companies.#Pharmaceutical #drug #companies

pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Pharmaceutical drug companies

Our products are available to local pharmaceutical distributors in most countries.

Pharmaceutical drug companies

Pharmaceutical drug companies

Our products are available under private label to our distributors and partners.

Pharmaceutical drug companies

Pharmaceutical drug companies

We work with our distributors, strategically programmatically, to accelerate, expand extend the product life cycles of ethical drugs.

Pharmaceutical drug companies

Pharmaceutical drug companies

We can provide, clinical Trials, FDA Certificates and BE Studies for registration of our products as per guidelines of most health authorities in most countries.





Home Page, PhRMA, new pharmaceutical companies 2013.#New #pharmaceutical #companies #2013

new pharmaceutical companies 2013

PhRMA represents the country’s leading biopharmaceutical research companies and supports the search for new treatments and cures.

Advocacy

From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.

Science

Today, cutting-edge medical science is transforming patients’ lives. Discover how scientists and researchers are advancing science.

Patients

Patient support and assistance is the top priority for PhRMA’s member companies, who are working hard to improve patients’ lives through the discovery and development of new medicines and treatments.

Resources

Explore the Resource Library, the interactive State Map and the Chart Pack reports.

Search the PhRMA Network

Stay Connected

Sign Up for Updates

New pharmaceutical companies 2013

Welcome to the future of medicine. Where together, we go boldly.

New pharmaceutical companies 2013

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

New pharmaceutical companies 2013

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

New pharmaceutical companies 2013

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

New pharmaceutical companies 2013

Learn more about America’s biopharmaceutical companies and how they seek to improve patients’ lives.

New pharmaceutical companies 2013

We Work For Health aims to increase awareness by uniting workers throughout the industry.

New pharmaceutical companies 2013

Patent protection should always be considered by an inventor during the initial stages of their invention.

New pharmaceutical companies 2013

Working to spread awareness and education about the importance of secure drug disposal.





Biotech Industry, Biotech News, Biotechnology Articles, actavis pharma manufacturing.#Actavis #pharma #manufacturing

actavis pharma manufacturing

Certain microRNAs in the saliva of concussion patients could help gauge the severity of concussions and predict the length of concussion symptoms.

Actavis pharma manufacturing

Toxicity knocks Ardelyx s hyperkalemia hopes back to preclinic

Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.

Actavis pharma manufacturing

Cytokinetics cans lead drug after phase 3 ALS wipeout

Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial.

Actavis pharma manufacturing

Step Pharma bags cash for CTPS1 autoimmune R D drive

The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.

Actavis pharma manufacturing

PTK6 blocker could treat or even prevent ER+ breast cancer metastasis

The enzyme PTK6 could be targeted to quell the growth of estrogen receptor-positive breast cancer, a common form of the disease.

Actavis pharma manufacturing

Amsterdam beats out Milan to host EMA

After tying with Milan in a third round of voting, Amsterdam will be the new home of the European Medicines Agency.

Actavis pharma manufacturing

LivaNova to offload Cardiac Rhythm unit for $190M

LivaNova will sell its Cardiac Rhythm Management business to its joint venture partner, MicroPort Scientific.

Actavis pharma manufacturing

DBV climbs as peanut allergy safety data come in clean

Shares in DBV rose on the back of the data, going a little way to erasing the big drop it suffered after missing its primary efficacy endpoint.

Actavis pharma manufacturing





10 Facts about the U, pharmaceutical containers.#Pharmaceutical #containers

First American Plastic

Pharmaceutical containers

As far as American manufacturing goes, the plastics sector is among the most notable success stories, helping to lead the way in economic recovery. Injection molding remains a vital part of the U.S. economy and a source for hundreds of thousands of jobs. Below are 10 facts that show the continued success of the injection mold industry based on data compiled by the Plastic Industry Trade Association, the American Chemistry Council and the U.S. Bureau of Labor Statistics.

1. In the United States, the plastics industry is the third-largest manufacturing industry. And the outlook is strong, with everything from injection molding companies to 3D printing in high demand around the world.

2. The plastics industry isn’t just massive — it actually translates to jobs. The industry employs nearly 900,000 workers in the United States alone, making plastics a key building block within manufacturing and for the U.S. job force overall. And that’s just part of the story — when you include plastics suppliers the number goes even higher, with the entire plastics industry accounting for roughly 1.4 million jobs nationally.

3. Injection molding and plastic manufacturing facilities can be found throughout the country in all 50 states. In fact, there are nearly 16,000 facilities just in the United States.

4. It’s a multi-billion dollar industry. In 2012, plastics manufacturers shipped about $373 billion in goods.

5. In an encouraging sign that plastics manufacturers are optimistic about their industry, they spent upwards of $10 billion in 2012 on new capital equipment.

6. It’s worth the investment. Already, plastics manufacturers are enjoying a surge in activity on the consumer side. In fact, consumption of plastic products went up 5.7 percent between 2011 and 2012.

7. The success of American plastic manufacturing depends in part on global interest; the world relies on U.S. plastic manufacturing. The top three countries that benefit from American plastics by way of U.S. exports are Mexico, Canada and China.

8. It’s no secret that manufacturing as a whole has taken a beating in recent decades — especially during the most recent recession — but plastics is among the sectors that are actually growing. In the last 25 years, manufacturing has dropped an average of 1.4 percent each year, while plastics manufacturing has increased at an average annual rate of 0.1 percent.

9. When compared with manufacturing as a whole, the plastics industry actually enjoys a sizable trade surplus, logging $13.1 billion in 2012.

10. How much actual plastic does this translate into? The answer: tons and tons. Roughly 107.5 billion pounds of plastics and resins were manufactured in 2013 — an increase over the previous year’s 105.9 billion pounds.





Some of These 101 Prescription Drugs – Made in Puerto Rico Before Hurricane Maria –

Some of These 101 Prescription Drugs Made in Puerto Rico Before Hurricane Maria May Soon Be Unavailable

So far, neither FDA nor the companies involved have provided a comprehensive list of the specific drugs that are manufactured in Puerto Rico (and that are thus at risk of shortages). By reviewing hundreds of government and industry documents we’ve assembled that list. It illustrates yet another reason why mainland Americans should care about Puerto Rican recovery: because the mainland and the island both depend on one another.

about this story at:

Actavis pharma manufacturing

Actavis pharma manufacturing

America’s Rapidly Emptying Drug Store: Hurricane-Ravaged Puerto Rico

When September’s Hurricane Maria plunged the island of Puerto Rico and its 3.4 million American citizens into a post-apocalyptic existence without reliable electricity or drinkable water conditions that remain today, more than a month later one of the least-noted casualties of that death-blow was the island’s largest manufacturing sector: pharmaceutical production.

The full implications of that disaster and of the glacially slow pace of subsequent FEMA-led recovery efforts now seem set to hit home for mainland Americans, who could soon face difficulties filling the prescriptions that many of our lives depend upon.

Thanks to a favorable U.S. tax code provision enacted in 1976, major pharmaceutical companies like Pfizer, Amgen, Bristol Myers Squibb, Lilly, and Johnson & Johnson have large factories located across the island of Puerto Rico. But post Maria those multimillion dollar facilities face the same impossible conditions that their workers’ families also face at home: faltering electrical service, failing backup generators, trickling tap water, and unreliable transportation.

U.S. Food and Drug Administration head Scott Gottlieb painted a bleak picture of what that means for those pharmaceutical plants in a recent interview with Reuters: A lot of companies say they’re online, but they basically have one of five lines running at 20 percent or 80 percent or 50 percent [. ] It’s unclear when they are going to be able to bring that up to full capacity. Underscoring the agency’s concern, Gottlieb’s FDA has announced that it is now closely monitoring “about 40 pharmaceutical and biological drug products for which a shortage could have substantial impact on the public health.”

Unfortunately for American patients who rely on those drugs, so far neither FDA nor the companies involved are saying which drugs might soon be in short supply. In fact very few Americans – apparently even including reporters covering this emerging story – know which drugs are manufactured in Puerto Rico.

Mind The Gap

To address that lack of information, Insightus researchers have just completed a survey of hundreds of documents that identify drugs currently manufactured on the island. Sources used in our analysis included publicly available FDA (and foreign drug regulators’) documentation, Securities and Exchange Commission filings, Federal Register notifications, drug package inserts, trade journals, court filings, scholarly studies, and other reliable sources.

Included in the resulting list of 101 Puerto Rico manufactured pharmaceuticals (see table below) are 9 of America’s top 20 bestselling drugs for 2016, including Humira (the #1 best-seller), Enbrel (#3), Remicade (#5), Januvia (#6), Lyrica (#8), Crestor (#9), Neulasta (#10), Xarelto (#14), and Eliquis (#16).

Cancer and chemotherapy-related conditions (10)





Insulated containers for temperature sensitive products, pharmaceutical containers.#Pharmaceutical #containers

pharmaceutical containers

Pharmaceutical containers

Pharmaceutical containers

Pharmaceutical containers

PED offer Europe’s widest range of re-usable insulated containers large and small for hundreds of temperature sensitive applications including food delivery, medical and military.

Pharmaceutical containers

Proven for over 25 years by logistics companies, supermarkets, food producers, home delivery operations, hospitals, government organisations and pharmaceutical companies. PED insulated containers are delivering cost effective and highly flexible solutions for temperature sensitive distribution around the World.

Pharmaceutical containers

We carefully select and stock the best quality products from around the world. FOLD-UP LIGHTWEIGHT EPP CONTAINERS NOW AVAILABLE!

Pharmaceutical containers

Our help desk is pleased to provide technical advice and suggestions for your project on 01933 403777 ROLL CAGE STYLE TEKTAINERS.

Pharmaceutical containers

The biggest names in business trust PED to solve their temperature sensitive problems;

Pharmaceutical containers

Catering/Hospitality

Insulated containers for every application including gastronorm compatible. From large scale Tektainers, mid sized Avatherm and small sized Thermexx. more

Pharmaceutical containers

Supermarket Delivery

Robust & built to last! Available in UK roll-cage, UK pallet, Euro pallet sizes . more

Pharmaceutical containers

Home Food Delivery

A wide range of high quality, lightweight EPP insulated containers for home delivery. more

Pharmaceutical containers

Scooter Delivery

Insulated containers for fast food, meals on wheels, gourmet & home delivery. more

Pharmaceutical containers

Food Processing

Insulated tubs suitable for fish and dry ice applications. more

Pharmaceutical containers

Medical/Bio Delivery

Extra thick double skinned walls for medical applications. Typically supplied for vaccine transportation. more

Pharmaceutical containers

Military Operations

Designed for the most demanding environments. more

Pharmaceutical containers

Heavy Duty Delivery

High quality, lightweight EPP container. Formed under extra tonnage for better long term performance. more

Pharmaceutical containers

Care Home Catering

Containers for individual and group meals. more

Pharmaceutical containers

Dry Ice Delivery

For safe storage & transportation of dry ice. Tested by leading UK dry ice specialists. more.

Pharmaceutical containers

Farmers Market Delivery

Transport your precious food and drink products to your desired event. more

Pharmaceutical containers

Disaster Relief

Approved for worldwide disaster relief. more

Pharmaceutical containers

Pharmaceutical containers





Medzilla; Biotech Jobs, Pharmaceutical Jobs, Pharmaceutical Sales Jobs, Resumes, Medical Career, Job Board, Biopharmaceutical Jobs,

MedZilla

  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies

  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies
  • Top 5 pharmaceutical companies

This Week’s Featured Jobs

Opportunity posted by Sunrise Systems Inc

Opportunity posted by Lexicon Pharmaceuticals

Opportunity posted by The Medical Affairs Company

Opportunity posted by Lexicon Pharmaceuticals

Opportunity posted by Takeda Pharmaceuticals

Opportunity posted by PDI, Inc

Opportunity posted by Novartis

Opportunity posted by Touchpoint Solutions

Opportunity posted by Lundbeck

Opportunity posted by inVentiv Health

View our Newest Jobs by State

View our Newest Jobs by Profession

Employers & Recruiters

Search now, thank us later:

Search our pre-screened candidates for the talents you need now for FREE!

– Mark S, Sales Executive

– James D, Lab Technichian

– T. Baker, University of Florida

– K. Dalton, Clinical Director

– S. Ohlinger, Pharmaceutical Sales Rep

– Thom B, ETS Systems

Job Seekers

Post your resume to become Medzilla Certified and start getting job offers NOW!

Post your Resume

Hot Topics on Our Forums

ICON offers up to 7K per calendar year for tuition reimbursement. Eligibility begins the 1st of the following month after date of hire.

Just wonder what CRO provide tuition reimbursement or yearly allowance for school. I am not asking about PMP or ACRP fees for exams etc. This would be for some one that wants to get their MBA, law degree etc.

Looking for advice from those who are in pharma Sales or recruit for pharma sales. I have always been interested in sales and at the same time I was applying to graduate schools for my teaching certificate, I was also applying to pharma. companies . Read More

Latest Articles

The MedZilla.com Employment Report: Permanent R ?>

Cafepharma Message Boards, Pharma Sales, Device Sales, Lab Sales, drug reps.#Drug #reps

drug reps

Drug reps

Shire vs.

Injunction against Misappropriation of Trade Secrets (contact info for rare disease MDs) Shire also suing three other ex-Shire RBM’s who went to the same company.

Drug reps

Goal setting is a joke

Has anyone in the A or C zones looked at growth YOY in radar? Goal setting is such a joke. Can’t management hire IC people who know what they are doing regarding goal setting? look at how many regions in the gulf and south east zones that are.

Drug reps

Light me a stick!

We partying to Puerto Rico! Big bonus coming!

Drug reps

Why Amgen culture sucks

Drug reps

The Mooral choice is clear

Idiot boy, he’s delivering on the agenda Christians want. You truly are stupid! :rolleyes:

Drug reps

Whats the best breast implant to get

Ever notice how a girl gets her boobs done and she’s semi thin at first then as soon as her boobs are done she gets bigger and bigger everywhere else? girls who get their boobs bigger think they look so good that they let everything go after.

Drug reps

Marriage is sacred in the midwest

Trying to be cute won’t save you. You’ve come off looking like the ignorant fool you are once again. :p:p:p:p:p:p





Aristo Pharma, zydus pharmaceuticals.#Zydus #pharmaceuticals

zydus pharmaceuticals

Source: Stockist Secondary Audit IMS – APR MAT’17 Dataset

Zydus pharmaceuticals

Corporate Standing

Source: Stockist Secondary Audit IMS – APR MAT’17 Dataset

Zydus pharmaceuticals

Brand Power

Ten brands in top 300 products of Indian Pharma Market

*Rank in total Indian Pharma Market

Source : Stockist Secondary Audit IMS – APR’17 Dataset

Zydus pharmaceuticals

Support for Buhari: Aggrieved Reps revolt against Dogara – The Nation Nigeria, drug reps.#Drug #reps

Support for Buhari: Aggrieved Reps revolt against Dogara

Drug reps

A rebellion is building up in the House of Representatives against Speaker Yakubu Dogara,according to multiple sources in the Green Chambers of the National Assembly.

Dogara’s offence is what many members perceive as his soft spot for the Presidency.

The Reps claim the Speaker want to turn the House into a rubber stamp for the executive arm.

They are also angry that constituency projects are not being implemented by the Executive,and want to know why about 50-60 per cent of them (members) have not been assigned their official cars.

Another grievance of the Reps is alleged lateness in payment of their salaries and allowances.

Dogara ,though shocked by the development,has launched a counter move to calm frayed nerves.

Majority of the Reps are said to have opted not to team up with the Senate to move against the Presidency,at least for now.

Investigation revealed that Dogara was jolted on Wednesday when some members of the House took him up on the various issues at an Executive Session.

It was learnt that a ranking member from Kano State led the protest by faulting the House leadership’s alleged romance with the presidency instead of asserting the independence of the chamber.

The members alleged that their support for the presidency, especially ailing President Muhammadu Buhari, was not being reciprocated by the latter.

They also complained about how ministers had been treating summons by committees with disdain.

They were particularly irked by the alleged unwillingness of the Executive to implement constituency projects in the 2016 budget.

Members claimed they went through hell to get the constituency projects executed.

A top source said: “Since he was elected, the Speaker has never had the type of revolt he witnessed during the week from members.

“The matter got to a point that some members at the plenary on Wednesday refused to stand up in deference to the Speaker in order to usher him into the chamber.

“Even on Thursday, some members extended their annoyance to voting during the debate on amendments to the 1999 constitution.”

Another ranking member gave said: “Some members from the North-West actually led the revolt at the Executive session. They accused Dogara of ‘leaning so much to the Executive’ such that the House was being turned into a rubber stamp.

“They gave a long list of constitutional violations by the Executive which the House ignored because of Dogara’s rapprochement with President Muhammadu Buhari and Acting President Yemi Osinbajo.

“They queried why the Minister of Power, Works and Housing, Mr. Babatunde Fashola will come out publicly to deride the House without any sanction. They cited cases of ministers and chief executives of MDAs not honouring House summons.

“Also, the MDAs, especially ministers, elect to implement constituency projects based on their whims and caprices. But they have always forgotten that the budget is a law. Some of us are tired and frustrated.

“The Speaker has been persuading us to be patient but we are not delivering dividends of democracy to our constituents. What we now get is stoning of some members by their constituents.

Another member from the South-South said: “Well, some of us actually complained bitterly about welfare matters. We are two years into our tenure and about 50-60 per cent of our members have not been given official cars.

“The complaint we have been getting borders on the fact that the Peugeot model cars have been ordered from abroad but yet to arrive. It is insulting that we have to be lobbying to get official cars which will be paid for from our entitlements.

“We believe that something was fundamentally wrong with the award of the contract for the cars by the House Services Committee.

“There was no communication on what has really happened. Unfortunately, the leadership has been tolerating the House Services Committee.”

A member from the North-West said: “It has not been funny because we get our salaries and allowances late.

“We protested to let the Speaker know that we are suffering in silence. If the Speaker had not handled it with maturity, we would have changed all the principal officers.

“ Of what use is backing President Buhari without meaningful projects in our constituency?

“Many of us preferred the Senate antagonistic method because it is working for that chamber. This was why we took on Dogara since the beginning of the week.”

But a principal officer said: “When Dogara opened up at the session, it was realized by members that he has not been pocketed by the presidency. His leadership style is that of consultation and not confrontation. He thinks service delivery to Nigerians should be the priority of lawmakers and not feud with the Executive.

“The same Speaker said he had engaged the Acting President on Fashola matter and Prof. Osinbajo directed the Minister to go and apologize. He obeyed the directive on Friday.

“In the last few months, the Speaker has been to the Villa to iron out issues amicably between the two arms of government.”

On the welfare of members, the principal officer said: “I think it has to do more with the failure of the House Services Committee than the problem with the Speaker. He was shocked to hear some of the complaints.”

Findings confirmed that following assurances from the Speaker, members jettisoned plans to “team up with the Senate” against the Executive.

“Dogara has sued for calm; we are giving him benefit of the doubt. He is a good listener but we need action.”

A member from the North-East said: “We have heard from Dogara and his team.We are awaiting action on their pledges to address our complaints. We love the Speaker, we have temporarily sheathed the swords.

“We have all collectively resolved not to join the Senate to fight the Executive because some of the issues are really too personal. Some have to do with sheer politics and ambition. We won’t be part of it.

“But the House leadership has suffered a jolt, the situation might never be the same henceforth. We love Dogara but we cannot sacrifice the interest of our constituents.”





Pharm Exec s Top 50 Companies 2017, Pharmaceutical Executive, top 5 pharmaceutical companies.#Top #5 #pharmaceutical

top 5 pharmaceutical companies

Pharm Exec’s latest annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.

With the exception of a few new bottom-end entrants, and some juggling of positions in the top half, stability remains the name of the game for those biopharmaceutical companies making up this year s list of the industry s top 50 global sales leaders (see tables below). Of course, the relative calm in the rankings meter doesn t mean that stability necessarily begets profitability for all. Amid growing pricing pressures, key patent losses for some, and a slowdown in M A activity since the middle of 2016, several mainstays on the Pharma 50 list experienced only modest revenue gains in the latest full-year figures collected, while others suffered slight declines. Pharm Exec s 17th annual listing again features data provided by biopharma market intelligence firm Evaluate Ltd.

Experts attribute the consistent entrenchment of familiar names in the top 10 and 20 to the simple adage of how business gets done in this industry mainly big pharma following a model that continues to prioritize amassing products and innovation through internal R D, licensing, or acquisition. Pfizer, for example, which repeated as the industry s prescription sales leader, has maintained its hold by applying the latter two. As have companies such as Shire, which spurred by its completed merger of Baxalta in June 2016, shot up from the 30th spot to No. 22 on this year s revenues list. And on the R D side, Shire s investment increased 45.5% to $1.29 billion.

Merck Co., despite being ranked fourth in sales, is No. 1 in R D spend, with a 47.6% spike in investment versus the previous year. The company s newest rising seller, the immunotherapy Keytruda, continues to be studied across numerous tumor types, lines of therapy, and combinations. Others that didn t climb the sales ranks but are investing solidly in R D include Lilly (15th in sales, eighth in R D spend) and AstraZeneca (11th in sales, seventh in R D).

As far as future shifts in sales-figure positioning in the Pharma 50, Jonathan Gardner, EP Vantage News Editor, US, at Evaluate, cites two areas to watch. The first is pricing, to the extent where payers become more assertive in areas where they have been reluctant in the past, such as oncology or orphan diseases, Gardner tells Pharm Exec. On the latter, we ve seen payers be surprisingly skeptical of new drugs Spinraza and Exondys 51, and there is potential for that to expand. The second issue is disease areas that have become crowded with new agents autoimmune disorders such as psoriasis and rheumatoid arthritis that could give payers even more leverage than they ve had in the past on franchises such as Humira and Enbrel.

Gardner also notes that until the outlook on US pricing legislation, tax reform, and repeal and replace of the Affordable Care Act becomes clearer, a big rush on M A is unlikely. Opportunistic deals will appear, but companies with significant amounts of overseas cash will be reluctant to risk overpaying on taxes to execute major US acquisitions, he says. Pricing and ACA repeal/replace pose similar, if lower-level risks.

Which leads us to our special Pharma 50 accompanying feature by guest authors at the executive search and talent advisory firm Russell Reynolds Associates. The authors contend that a significant disruptive event looms on the horizon for the industry, brought on by new US legislation on pricing and new definitions of value. The article points out that traditional sourcing routes for biopharma innovation in-licensing, M A, and R D collaboration have been expanded by new models of engagement with external innovators, such as open innovation models and corporate ventures. Managing the diversity and complexity of these innovations, and building a more nuanced communication with the external world, will require all those companies in our Pharma 50 to adopt new leadership approaches and install new types of specialists and C-suite roles to guide the collective industry through the coming disruption and beyond.

See how the top 50 biopharma revenue generators stack up ahead (click on the tables to enlarge).

Top 5 pharmaceutical companies Top 5 pharmaceutical companies Top 5 pharmaceutical companies Top 5 pharmaceutical companies Top 5 pharmaceutical companies





Pharmaceutical Companies of Johnson & Johnson, Janssen, top 20 pharmaceutical companies.#Top #20 #pharmaceutical #companies

top 20 pharmaceutical companies

We engage in approximately 400 active collaborations — from discovery to late-stage development — with academia, pharmaceutical and biotech peers, and other public- and private-sector partners.

Partner With Us

Together, we can solve problems

and find transformational solutions.

We believe that partnerships are essential to drive change, innovation and transformation, and we are committed to ensuring the success of our collaborations.

Top 20 pharmaceutical companies

Betsy Gross

Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses.

Top 20 pharmaceutical companies

Cliff Enright

Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses. Learn more about Cliff’s story, “A Colorful Life”.

Top 20 pharmaceutical companies

Dennis Owen Frohlich

Green Tree Repaint

Diagnosed with ulcerative colitis in 2007, Dennis created an educational website to share his story. Today, his academic career focuses on health communication and exploring the internet’s role in promoting health and well-being.

Top 20 pharmaceutical companies

Dorethey Gorham

Day Of The Armada

Dorethey is a joyful, self-taught artist living with arthritis, general anxiety syndrome and diabetes.

Top 20 pharmaceutical companies

Jane Kielt

A retired art teacher and world traveler, Jane has had a passion for art since childhood. Through painting watercolors, she finds inspiration and healing throughout her experience living with multiple myeloma. Learn more about Jane by reading her story “The Art of Getting Lost.”

Top 20 pharmaceutical companies

Jennifer Jacobs Baruch

Jennifer is a New York–based artist living with type 1 diabetes.

Top 20 pharmaceutical companies

Melinda

Melinda’s artwork reflects her journey living with HIV.

Top 20 pharmaceutical companies

Rhonda Fenwick

Through her art, Rhonda has explored psoriasis, a chronic skin disorder she has lived with since the age of six.

Top 20 pharmaceutical companies

Robert Wright

Artwork from the National Art Exhibitions of the Mentally Ill, Inc. (NAEMI), an organization dedicated to discovering and preserving the art of people with mental illness.

Top 20 pharmaceutical companies

Top 20 pharmaceutical companies

Betsy Gross

Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses.

Tap here to expand

Top 20 pharmaceutical companies

Top 20 pharmaceutical companies

Cliff Enright

Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses. Learn more about Cliff’s story, “A Colorful Life”.

Tap here to expand

Top 20 pharmaceutical companies

Top 20 pharmaceutical companies

Dennis Owen Frohlich

Green Tree Repaint

Diagnosed with ulcerative colitis in 2007, Dennis created an educational website to share his story. Today, his academic career focuses on health communication and exploring the internet’s role in promoting health and well-being.

Tap here to expand

Top 20 pharmaceutical companies

Top 20 pharmaceutical companies

Dorethey Gorham

Day Of The Armada

Dorethey is a joyful, self-taught artist living with arthritis, general anxiety syndrome and diabetes.

Tap here to expand

Top 20 pharmaceutical companies

Top 20 pharmaceutical companies

Jane Kielt

A retired art teacher and world traveler, Jane has had a passion for art since childhood. Through painting watercolors, she finds inspiration and healing throughout her experience living with multiple myeloma. Learn more about Jane by reading her story “The Art of Getting Lost.”





Pharmaceutical industry gets high on fat profits – BBC News, top 5 pharmaceutical companies.#Top #5

Pharmaceutical industry gets high on fat profits

Share this with Facebook

  • Share this with Twitter

  • Share this with Messenger

  • Share this with Messenger

  • Share this with

    These are external links and will open in a new window

    Share this with Facebook

  • Share this with Messenger

  • Share this with Messenger

  • Share this with Twitter

  • Share this with Pinterest

  • Share this with WhatsApp

  • Share this with LinkedIn

  • These are external links and will open in a new window

    Close share panel

    Imagine an industry that generates higher profit margins than any other and is no stranger to multi-billion dollar fines for malpractice.

    Throw in widespread accusations of collusion and over-charging, and banking no doubt springs to mind.

    In fact, the industry described above is responsible for the development of medicines to save lives and alleviate suffering, not the generation of profit for its own sake.

    Pharmaceutical companies have developed the vast majority of medicines known to humankind, but they have profited handsomely from doing so, and not always by legitimate means.

    Last year, US giant Pfizer, the world’s largest drug company by pharmaceutical revenue, made an eye-watering 42% profit margin. As one industry veteran understandably says: “I wouldn’t be able to justify [those kinds of margins].”

    Stripping out the one-off $10bn (£6.2bn) the company made from spinning off its animal health business leaves a margin of 24%, still pretty spectacular by any standard.

    In the UK, for example, there was widespread anger when the industry regulator predicted energy companies’ profit margins would grow from 4% to 8% this year.

    Last year, five pharmaceutical companies made a profit margin of 20% or more – Pfizer, Hoffmann-La Roche, AbbVie, GlaxoSmithKline (GSK) and Eli Lilly.

    ‘Profiteering’

    With some drugs costing upwards of $100,000 for a full course, and with the cost of manufacturing just a tiny fraction of this, it’s not hard to see why.

    Last year, 100 leading oncologists from around the world wrote an open letter in the journal Blood calling for a reduction in the price of cancer drugs.

    Dr Brian Druker, director of the Knight Cancer Institute and one of the signatories, has asked: “If you are making $3bn a year on [cancer drug] Gleevec, could you get by with $2bn? When do you cross the line from essential profits to profiteering?”

    And it’s not just cancer drugs – between April and June this year, drug company Gilead clocked sales of $3.5bn for its latest blockbuster hepatitis C drug Sovaldi.

    Drug companies justify the high prices they charge by arguing that their research and development (R D) costs are huge. On average, only three in 10 drugs launched are profitable, with one of those going on to be a blockbuster with $1bn-plus revenues a year. Many more do not even make it to market.

    But as the table below shows, drug companies spend far more on marketing drugs – in some cases twice as much – than on developing them. And besides, profit margins take into account R D costs.

    The industry also argues that the wider value of the drug needs to be considered.

    “Drugs do save money over the longer term,” says Stephen Whitehead, chief executive of the Association of the British Pharmaceuticals Industry (ABPI).

    “Take hepatitis C, a shocking virus that kills people and used to require a liver transplant. At £35,000 [to £70,000] for a 12-week course, 90% of people are now cured, will never need surgery or looking after, and can continue to support their families.

    “The amount of money saved is huge.”

    True, but just because you can charge a high price for something does not necessarily mean you should, especially when it comes to health, critics such as Dr Druker might say. Shareholders, who big pharma companies ultimately have to answer to, would have little time for such an argument.

    No loyalty

    Big pharma companies also say they only have a limited time in which to make profits. Patents are generally awarded for 20 years, but 10-12 of those are typically spent developing the drug at a cost of about $1.5bn-$2.5bn.

    This leaves eight to 10 years to make money before the formula can be taken up by generic drug companies, which sell the medicines for a fraction of the price.

    Once this happens, sales fall by 90%-plus. As Joshua Owide, director of healthcare industry dynamics at research company GlobalData, explains, “Unlike other sectors, brand loyalty goes out the window when patents expire.”

    This is why pharma companies go to such extraordinary lengths to extend their patents – a process known as evergreening – employing “floors full of lawyers” for this express purpose, one industry insider says.

    For a drug raking in $3bn a quarter, even a one-month extension can be worth huge sums of money.

    New formulations, combining two existing drugs to give a wider use, and enantiomers – a mirror image of the same compound – are some of the legal ways to eke out patents. But some drug companies, including the UK’s GSK, have been accused of more underhand tactics, such as paying generics to delay the release of their cheaper alternatives.

    As the loss of sales at the big pharma companies far outweighs the revenue made by the generics, this can be an attractive arrangement for both parties.

    Courting doctors

    But drug companies have been accused of, and admitted to, far worse.

    Until recently, paying bribes to doctors to prescribe their drugs was commonplace at big pharmas, although the practice is now generally frowned upon and illegal in many places. GSK was fined $490m in China in September for bribery and has been accused of similar practices in Poland and the Middle East.

    The rules on gifts, educational grants and sponsoring lectures, for example, are less clear cut, and these practices remain commonplace in the US.

    Indeed a recent study found that doctors in the US receiving payments from pharma companies were twice as likely to prescribe their drugs.

    This may well exacerbate the problem of overspending on drugs by governments. A recent study by Prescribing Analytics suggested that the UK’s National Health Service could save up to £1bn a year by doctors switching from branded to equally effective generic versions of the drugs.





    Instructions to Authors, INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, international pharmaceutical abstracts.#International #pharmaceutical #abstracts

    Instructions to Authors

    The International Journal of Pharmaceutical Sciences and Research (www.ijpsr.com) is a monthly published online and print Journal, which publishes innovative research papers, reviews, mini-reviews, short communications and notes dealing with Pharmaceutical Sciences (Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest). All manuscripts are subject to rapid peer review. Those of high quality (not previously published and not under consideration for publication in another journal) will be published without delay.

    The preferred format of all manuscript is MS Word. Illustrations (figures) and images must be inserted in the manuscript at the position they should appear when published.

    Preparation of Manuscript

    Mode of Presenting Paper is English. Each manuscript should be typed single-spaced on A4 (8.5 × 11 ) paper size with 1 inch margins. It should be arranged in the following order: Title, Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement and References.

    Title page should contain title of the paper in bold face, title case (font size 14), names of the authors in normal face, upper case (font size 12) followed by the address in normal face lower case. The author to whom all correspondence be addressed should be denoted by an asterisk mark. The title should be as short as possible and precisely indicate the nature of the work in the communication. Names of the authors should appear as initials followed by surnames. At the bottom left corner of the title page, please mention “*Address For correspondence” and provide a functional e-mail address. Address of the corresponding author to whom all correspondence may be sent should be given only if it is different from the address already given under authors names.

    Should start on a new page after the title page and should be typed in single-space to distinguish it from the Introduction. Abstracts should briefly reflect all aspects of the study, as most databases list mainly abstracts. The manuscript should have an abstract 150- 250 words.

    Provide four to six appropriate key words after abstract

    A short introduction of the research problem followed by a brief review of literature and objective of the research.

    Describe the materials used in the experiment, year of experimentation, site etc. Describe the methods implied for collection of data in short.

    This segment should focus on the fulfillment of stated objectives as given in the introduction. It should contain the findings presented in the form of tables, figures and photographs.

    Should be numbered consecutively in the order in which they are first mentioned in the text (not in alphabetic order). Identify references in text, tables and legends by Arabic numerals in superscript. References cited only in tables or figure legends should be numbered in accordance with the sequence established by the first identification in the text of the particular table or figure.

    Shashi A, Jain SK and Pandey M: In-vitro evaluation of antilthiatic activity of seeds of Dolichos biflorus and roots of Asparagus racemosus . International Journal of Plant Sciences 2008; 1:67-71.

    Kalia AN: A Text Book of Industrial Pharmacognosy. CBS Publishers Distributors, First Edition 2005.

    Nadkarni KM: Indian Materia Medica. Popular Prakashan, Mumbai, Edition 3, Vol. I, 2000: 242-246.

    All the tables and figures should be in the text at suitable place. Only MS word table format should be used for preparing tables. Tables should show lines separating rows but not those separating columns. Tables should be numbered consecutively in Arabic numerals and bear a brief title in capital letters normal face. Tables should not be very large that they run more than one A4 sized page. Table format should be as follow:

    Phytochemical Analysis of successive extract of





    Pharmaceutical Companies of Johnson & Johnson, Janssen, top 5 pharmaceutical companies.#Top #5 #pharmaceutical #companies

    top 5 pharmaceutical companies

    We engage in approximately 400 active collaborations — from discovery to late-stage development — with academia, pharmaceutical and biotech peers, and other public- and private-sector partners.

    Partner With Us

    Together, we can solve problems

    and find transformational solutions.

    We believe that partnerships are essential to drive change, innovation and transformation, and we are committed to ensuring the success of our collaborations.

    Top 5 pharmaceutical companies

    Betsy Gross

    Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses.

    Top 5 pharmaceutical companies

    Cliff Enright

    Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses. Learn more about Cliff’s story, “A Colorful Life”.

    Top 5 pharmaceutical companies

    Dennis Owen Frohlich

    Green Tree Repaint

    Diagnosed with ulcerative colitis in 2007, Dennis created an educational website to share his story. Today, his academic career focuses on health communication and exploring the internet’s role in promoting health and well-being.

    Top 5 pharmaceutical companies

    Dorethey Gorham

    Day Of The Armada

    Dorethey is a joyful, self-taught artist living with arthritis, general anxiety syndrome and diabetes.

    Top 5 pharmaceutical companies

    Jane Kielt

    A retired art teacher and world traveler, Jane has had a passion for art since childhood. Through painting watercolors, she finds inspiration and healing throughout her experience living with multiple myeloma. Learn more about Jane by reading her story “The Art of Getting Lost.”

    Top 5 pharmaceutical companies

    Jennifer Jacobs Baruch

    Jennifer is a New York–based artist living with type 1 diabetes.

    Top 5 pharmaceutical companies

    Melinda

    Melinda’s artwork reflects her journey living with HIV.

    Top 5 pharmaceutical companies

    Rhonda Fenwick

    Through her art, Rhonda has explored psoriasis, a chronic skin disorder she has lived with since the age of six.

    Top 5 pharmaceutical companies

    Robert Wright

    Artwork from the National Art Exhibitions of the Mentally Ill, Inc. (NAEMI), an organization dedicated to discovering and preserving the art of people with mental illness.

    Top 5 pharmaceutical companies

    Top 5 pharmaceutical companies

    Betsy Gross

    Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses.

    Tap here to expand

    Top 5 pharmaceutical companies

    Top 5 pharmaceutical companies

    Cliff Enright

    Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses. Learn more about Cliff’s story, “A Colorful Life”.

    Tap here to expand

    Top 5 pharmaceutical companies

    Top 5 pharmaceutical companies

    Dennis Owen Frohlich

    Green Tree Repaint

    Diagnosed with ulcerative colitis in 2007, Dennis created an educational website to share his story. Today, his academic career focuses on health communication and exploring the internet’s role in promoting health and well-being.

    Tap here to expand

    Top 5 pharmaceutical companies

    Top 5 pharmaceutical companies

    Dorethey Gorham

    Day Of The Armada

    Dorethey is a joyful, self-taught artist living with arthritis, general anxiety syndrome and diabetes.

    Tap here to expand

    Top 5 pharmaceutical companies

    Top 5 pharmaceutical companies

    Jane Kielt

    A retired art teacher and world traveler, Jane has had a passion for art since childhood. Through painting watercolors, she finds inspiration and healing throughout her experience living with multiple myeloma. Learn more about Jane by reading her story “The Art of Getting Lost.”





    Top 10 Pharmaceutical Companies in India, Top Pharma Company in India, pharmaceutical companies list.#Pharmaceutical #companies

    Top 10 Pharmaceutical Companies in India

    In the list of top pharmaceutical companies in India it is not the Indian companies but also the MNCs that are becoming the part of the race. Indian pharmaceutical market in 2008 was $7,743m and if compared to year 2007 it was 4% more than that. It is expected that Indian pharmaceutical market will grow more than the global pharmaceutical market and will become $15,490 million in 2014. Today Indian pharmaceutical industry is the second most fastest growing industry displaying the revenue of Rs 25,196.48 crore and growth of 27.32 percent. Top pharmaceutical companies in India are also acquiring the small companies worldwide to further expand the market. Pharmaceutical drugs injections, tablets, capsules, syrups are the products of pharma companies in India along with many more.

    Find below the list of latest Top 10 pharma companies in India by Net Sales (BSE):

    With total net sales of Rs 7686.59 crore, Ranbaxy is the largest pharmaceutical company in India.

    With total net sales of Rs 6,977.50 crore Cipla is the second largest pharmaceutical company in India.

    With total net sales of Rs 6,686.30 crore Dr Reddys Labs is the third largest pharmaceutical company in India.

    Lupin is the fourth largest pharma company in India with the total net sales of Rs 5,364.37 crore.

    Aurobindo Pharma is on 5th position with the total net sales of Rs 4,284.63 crore.

    Net Sales revenues stood at Rs 4,015.56 crore makes it the sixth largest pharmaceutical company in India.

    Cadila Health is the seventh largest pharma company with the total sales revenue of Rs 3,152.20 crore.

    Eight largest company has the total sale revenue at Rs 2,641.07 crore.

    Wockhardt has the total net sales of 2,560.16 crore and the ninth largest pharmaceutical company in India.

    Revenue of Rs 2,352.59 crore makes Ipca India’s 10th largest pharma firm by sales.

    Pharmaceutical companies list

    History of Indian Pharma Industry:

    Looking back into history reveals that it was in 1930 when the first pharmaceutical company in India came into existence in Kolkatta. It is called the “Bengal Chemicals and Pharmaceutical Works”. This Indian company is still there and today it is the part of five drug manufacturing companies that are owned by the government. Till the period of 60 years the pharmaceutical industry in India was overshadowed by the foreign drug manufacturing companies but with the Patent Act in 1970, the whole scenario of pharmaceutical companies in India had changed since then. With this the Indian market was more open to Indian pharmaceutical companies than the MNCs. So with this pharmaceutical companies in India started to grow in number At present there is a cut throat competition among top pharmaceutical companies in India with the native as well as MNCs. But there are certain issues that are concerning the growth of pharma companies in India. These are:

      Pharmaceutical companies list
    • Mandatory licensing and failure of new paten system.
    • Regular power cuts and inadequate infrastructure.
    • Restricted funding.
    • Regulatory hindrances that lead to the delays in the launch of new drug or pharma product.
    • Too many small as well as big pharmaceutical companies and excessive competition.




    Noven – About, kv pharmaceutical.#Kv #pharmaceutical

    Noven is a fully-integrated specialty pharmaceutical company with industry-leading transdermal expertise

    Board of Directors

    Kv pharmaceutical

    DR. NARUHITO HIGO
    Board Chairman

    Hisamitsu Pharmaceutical Co., Inc.

    Kv pharmaceutical

    Toshiaki tsuruda
    Vice Chairman

    and Head of Production Division –

    Hisamitsu Pharmaceutical Co., Inc.

    JEFF MIHM
    Director

    Noven Pharmaceuticals, Inc.

    Noven Officers

    Jeff Mihm
    Chief Executive Officer

    Jeff Mihm serves as Noven’s Chief Executive Officer since January 2016, and was appointed to its Board of Directors in August 2016. Mr. Mihm has held senior leadership positions of increasing scope and importance since joining Noven in 2003. Most recently, he served as Vice President, Chief Administrative Officer General Counsel, where he oversaw Noven s Business Development, Corporate Affairs, Human Resources, Information Technology and Legal/Compliance functions. Prior to Noven, Mr. Mihm served as Senior Corporate Counsel to Panamerican Beverages, Inc. (at the time, one of the world s largest Coca-Cola bottlers), and previously was a partner the law firm of Steel Hector Davis (now part of Squire Patton Boggs).

    JOHN CHOI
    Vice President, Chief Financial Officer Treasurer

    John Choi is Noven s Vice President, Chief Financial Officer and Treasurer. Mr. Choi, who joined Noven in 2010, most recently served Noven as its Executive Director – Business Planning Analysis. Prior to Noven, Mr. Choi served as Director of Commercial Operations Planning for Ther-Rx (a branded pharmaceutical division of KV Pharmaceuticals). Previously, he served Abbott Laboratories in various positions in the manufacturing operations, cost accounting, finance and international divisions, and served as an expatriate at Abbott s Korean affiliate, where he held leadership roles in financial planning and analysis and other commercial leadership roles.

    Patrick Gallagher
    Vice President – Business Development

    Patrick Gallagher joined Noven in February 2010 and serves as Vice President – Business Development. He has over 25 years’ experience in the pharmaceutical, biotechnology and drug delivery industries. Prior to joining Noven, he served as Senior Vice President, Business Development, Marketing & Sales at Acusphere. Previously, he served as Vice President, Corporate Business Development at Mylan Laboratories. Earlier, he held senior director positions at Bristol-Myers Squibb and Johnson & Johnson. As a corporate development and strategic planning consultant, he has also helped pharmaceutical, biotech and medical device industry clients develop and successfully execute critical business initiatives. Mr. Gallagher earned a B.Sc. degree from LaSalle University and an M.B.A. from The Wharton School of the University of Pennsylvania.

    MICHAEL GREENE
    Vice President, General Counsel Corporate Secretary

    Michael Greene is Noven s Vice President, General Counsel and Corporate Secretary. Mr. Greene previously served as Noven s Deputy General Counsel Executive Director – Alliance Management. From 2005 to 2010, Mr. Greene was an attorney at the law firm of Paul, Hastings, Janofsky Walker, where he specialized in mergers and acquisitions (M A) and other complex corporate transactions, including pharmaceutical industry transactions. Previously, he was an attorney with the law firm of Hunton Williams specializing in M A transactions and corporate law.

    MARK JACKSON
    Vice President – Quality

    Mark Jackson joined Noven in February 2017 and serves as Vice President – Quality. Mr. Jackson has over 30 years’ experience in the pharmaceutical and medical device industries. He joined Noven from HeartWare, Inc., a global medical device company specializing in the treatment of heart failure, where he served as the Vice President of Quality and Design Assurance. Previously, Jackson was at Baxter Healthcare Corp where he held positions of increasing responsibility including, Vice President Medical Products Quality, Vice President Quality, Renal Division/Global Technical Service and Plant Manager.

    RALPH LIPP, PH.D.
    Vice President and Chief Scientific Officer

    Dr. Ralph Lipp joined Noven in October 2016 and serves as Vice President and Chief Scientific Officer. Dr. Lipp has more than 25 years of experience in transdermals and drug delivery including 14 years at Schering A.G., where he rose to the position of Head of Pharmaceutical Development. He also served as the Vice President Pharmaceutical Sciences R ?>

    Top Biosimilars Conference in 2018, Biosimilars 2018, Largest Biologics Conferences, USA, Europe, Asia, international pharmaceutical

    Biologics and Biosimilars

    Theme: Emerging Trends in Biosimilars Approvals, Market and Pricing

    Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

    Explore and learn more about Conferenceseries Ltd: World s leading Event Organizer

    Conference Series Conferences gaining more Readers and Visitors

    Conference Series Web Metrics at a Glance

    • 3000+ Global Events
    • 25 Million+ Visitors
    • 25000+ unique visitors per conference
    • 70000+ page views for every individual conference

    Unique Opportunity! Online visibility to the Speakers and Experts

    Recommended Global Pharma Marketing & Industry Conferences

    USA Americas
    Europe UK
    Asia Pacific Middle East

    Biosimilars 2018

    To Collaborate Scientific Professionals around the World

    Conference Date October 24-25, 2018

    For Sponsors Exhibitors

    Useful Links

    Past Conference Report

    Supported By

    All accepted abstracts will be published in respective Conferenceseries International Journals.

    Abstracts will be provided with Digital Object Identifier by

    Quick Links

    • Abstracts Submission

    Conference Highlights

    Conferences By Continents

    USA Americas

    Asia-Pacific Middle East

    Europe UK

    Medical Clinical Conferences

    Conferences By Subject

    Mail us at

    ” class=”wrap-link”> Kiara Dcruize

    Contact us at

    International pharmaceutical abstracts

    13 th International Conference on Biologics and Biosimilars

    Please leave a message and someone will get back to you shortly.

    • Australia – Toll Free Numbers – 1-800-651-097
    • France – Toll Free Numbers – 0805-080048
    • Hyderabad – Toll Free Numbers -91-40-71279012
    • Hyderabad – Toll Free Numbers -91-40-71279013
    • UK – 0-800-014-8923
    • Los Angeles Downtown – 1-213-233-9462
    • USA/Canada – 1-888-843-8169

    Be a member and support us

    Follow us

    Authorization Policy

    By registering for the conference you grant permission to Conferenceseries Ltd to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.





    Pharmaceutical Wholesalers, pharmaceutical suppliers.#Pharmaceutical #suppliers

    pharmaceutical suppliers

    Pharmaceutical suppliers Canadian product list (NOTE: WE DO NOT SELL NARCOTICS). Use CTRL+F, then type the product you are looking for and hit enter to find it within the list faster.

    Results from the internet for ‘pharmaceutical suppliers Canada’:

    Google Directory – Business Biotechnology and Pharmaceuticals . A division of IT Pharmaceutical Supplies, Ltd. A wholesale medicines . Distributor of pharmaceuticals, surgical and laboratory equipment based in Canada. .

    www.google.com/Top/Business/Biotechnology_and_Pharmaceuticals/Pharmaceuticals/Wholesale_and_Distribution/ – 53k – Cached – Similar pages

    ca.dir.yahoo.com/Business_and_Economy/Business_to_Business/Health_Care/Pharmaceuticals/ – 103k – Cached – Similar pages

    www.aipharma.com/Pharmaceutical_Supplier_New_Zealand.htm – 24k – Cached – Similar pages

    www.aipharma.com/Pharmaceutical_Supplier_USA.htm – 2k – Cached – Similar pages

    [ More results from www.aipharma.com ]

    www.business.com/directory/pharmaceuticals_and_biotechnology/distributors_and_wholesalers/ – 79k – Cached – Similar pages

    naturalhealthcare.ca/suppliers.phtml?st=1 find=Search+Types prov=ON city=Scarborough – 11k – Cached – Similar pages

    naturalhealthcare.ca/suppliers.phtml?st=1 find=Search+Types prov=ON city=Richmond+Hill – 11k – Cached – Similar pages

    listingsca.com/British-Columbia/Southwest/Greater-Vancouver/Health/Pharmaceutical/ – 24k – Cached – Similar pages

    www.vetproducts.net/veterinary_medicine_supplies.php?vet_supply=veterinary_pharmaceutical_suppliers c. – 30k – Cached – Similar pages

    site:www.devicelink.com Medical Supplier Canada Software . Your search for: site:www.devicelink.com Medical Supplier Canada Software . Product Manufacturing News IVD Technology Pharmaceutical Medical Packaging .

    www.spothealthcare.com/keyword,site:www.devicelink.com+Medical+Supplier+Canada+Software,mhps,400/search.htm – 121k – Cached – Similar pages

    listingsca.com/Ontario/Toronto-Region/Health/Pharmaceutical/ – 24k – Cached – Similar pages

    www.contactcanada.com/pharma/ – 10k – Cached – Similar pages

    www.frasers.com/directory/companies.cfm?OfficeID=0 UserSearch=B SearchBy=A Keyword=Conveyors. – Similar pages

    www.elviano.com/ – 4k – Cached – Similar pages

    www.thepigsite.com/directory/2/north-america/35/pharmaceutical-companies-suppliers – 27k – Cached – Similar pages

    www.devicelink.com/company/pmp/category/Pharmaceutical_Packaging_Supplies/Stoppers.html – 24k – Cached – Similar pages

    www.devicelink.com/company/pmp/alpha/c.html – 31k – Cached – Similar pages

    [ More results from www.devicelink.com ]

    www.univarcanada.com/pharmaceutical.htm – 18k – Cached – Similar pages

    www.provincialpaper.com/products.asp – 18k – Cached – Similar pages

    Herbal Medicinal Ingredients Co-enzyme Q10 (Trafa Pharmaceutical . Trafa Pharmaceutical Supplies is an Alibaba supplier that manufactures Herbal Medicinal Ingredients Co-enzyme Q10 in Canada. Herbal Medicinal Ingredients .

    www.alibaba.com/catalog/11388859/Herbal_Medicinal_Ingredients_Co_enzyme_Q10.html – 23k – Cached – Similar pages

    www.globalsources.com/manufacturers/Pharmaceutical/suppliers.html – 88k – Cached – Similar pages

    www.globalsources.com/manufacturers/x/Pharmaceutical/Hong_Kong-Suppliers-of-Products.html – 99k – Cached – Similar pages

    www.gattefossecanada.ca/en/suppliers/ – 24k – Cached – Similar pages

    Pfizer Canada Global Pharmaceuticals;. and. Pfizer Animal Health . Please refer to the Supplier page on www.pfizer.ca for further information and updates.

    www.pfizer.ca/local/files/english/supplier/PGP-PGM-PAH%20Supplier%20Guide.pdf – Similar pages

    www.univarcanada.net/suppliers-pharmaceutical.htm – 20k – Cached – Similar pages

    www.cmaj.ca/cgi/reprint/170/7/1115.pdf – Similar pages

    www.pharmaceutical-industry.info/modules/pharmaceutical_suppliers/pharma_index_21_30.html – 25k – Cached – Similar pages

    www.elviano.com/Pharmaceutical.htm – 4k – Cached – Similar pages

    www.packwire.com/news-by-product/news.asp?id=77731 idCat=106 k=Wal-Mart–packaging-waste – 43k – Cached – Similar pages

    Pharmaceutical supplier makes play for distributor – The Business . Pharmaceutical supplier makes play for distributor. . Corporate executives to join governor on Canada trip · Obama rallies in Tempe, favors legal path for .

    3/169965261/focus7.html – 103k – Cached – Similar pages

    3 Positive and negative aspects of Canada’s legislation . pharmaceutical supplier, be it a brand-name company or a generic one? The fact that a .

    www.aidslaw.ca/publications/interfaces/downloadFile.php?ref=725 – Similar pages

    www.castingsnet.com/d/search.php?keyword=Pharmaceutical nstart=1 – 43k – Cached – Similar pages

    www.ctc.ca/news.asp – 18k – Cached – Similar pages

    phoenix.bizjournals.com/phoenix/stories/2007/10/15/focus7.html – 104k – Cached – Similar pages

    www.aimglobal.org/members/news/PPLTB/58-harmaceuticaldistrib.aspx – Similar pages

    www.business.com/directory/pharmaceuticals_and_biotechnology/equipment_and_supplies/ – 66k – Cached – Similar pages

    www.sulekhab2b.com/Sell/Search/draximage-canada.htm – 35k – Cached – Similar pages

    www.pharmaceuticals1.com/register.html – 16k – Cached – Similar pages

    www.healthpolitics.org/program_transcript.asp?p=canada_online_pharmacies – 17k – Cached – Similar pages

    Pharmaceutical Suppliers Directory, Pharma Technology . Latest developments in pharmaceutical and biopharmaceutical contract manufacturing and . AFP: Ex-health officials acquitted in Canada HIV scandal .

    www.pharmaceutical-int.com/ – 35k – Cached – Similar pages

    www.omya-na.com/ – 26k – Cached – Similar pages

    In 2000, a struggling pharmacist in Manitoba, Canada, came up with an innovative strategy to . Second, pharmaceutical suppliers tailored sales to Canadian .





    GMP and CMC Laboratory Services, cmc pharmaceutical.#Cmc #pharmaceutical

    GMP and CMC Laboratory Services

    Cmc pharmaceutical

    GMP and CMC laboratory services to support pharmaceutical development; method development, validation, stability, formulation, batch release and extractables/leachables

    Chemistry, manufacturing and controls (CMC) development strategies and Good Manufacturing Practice (GMP) laboratory services play a key role in helping you to reach your next milestone.

    We provide regulatory-driven, phase-appropriate, CMC laboratory and GMP analytical services. Our expertise ensures sufficient information for your Investigational New Drug (IND), Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) filings. This is achieved through analysis services, preformulation and solid state characterisation, method development and validation, stability studies, pharmaceutical impurity analysis, extractables and leachables and GMP batch release testing. Our scientists are adept at applying advanced technology in GMP compliant analytical development programs.

    Our formulation development scientists are experienced across a range of dosage forms including orally inhaled and nasal drug products (OINDP), oral, solid, liquid and transdermal or topical. Strategic integration of formulation development with analytics ensures a detailed understanding of the pharmaceutical materials, their compatibility, physical properties and stability. Our development teams offer cost-effective GMP Manufacturing Services for clinical trials aligned with IND or Common Technical Document CTD support which includes raw material characterization, sourcing, scale-up and pilot batch manufacturing to ensure product quality.

    With an experienced eye on current regulatory guidance, our formulation and analytical scientists work with you to utilize exactly the right techniques to deliver the data you need to take the next step for both small molecule pharmaceuticals or biopharmaceuticals. With over 20 years of experience, we can help you to meet the appropriate quality and regulatory standards at each stage.





    ProQuest Dialog, Multidisciplinary Content Collections for Professional Research – ProQuest Dialog™, international pharmaceutical abstracts.#International #pharmaceutical

    ProQuest Dialog™

    International pharmaceutical abstracts

    Fast Facts

    Specialized search & workflow tools for all users

    User-friendly interface & flexible payment plans

    Intended For

    Corporate

    Government

    Get Started

    Overview

    Dialog pioneered the online information industry in the early 1970s, delivering content from the world s most authoritative sources. Today, ProQuest Dialog continues to be a market-leading provider of premium content now in a user-friendly, flexible interface with specialized workflow tools enabling the novice searcher and expert information professional to quickly find, organize, and share the right information helping uncover new opportunities and drive innovation across the organization.

    Customer Resources | Administrator Resources

    What’s New

    International pharmaceutical abstracts

    ProQuest Dialog API

    Use our API to integrate authoritative content into your organization’s own workflow tools such as intranet sites, analysis/visualization programs or other third-party or proprietary solutions.

    International pharmaceutical abstracts

    ProQuest Dialog News Trade Collection

    The most complete collection for monitoring global news and trade press across all key industries, from the world’s major licensed media publishers with content not freely available online.

    International pharmaceutical abstracts

    Global Support Training

    1 800 334 2564 (North America)

    00 800 33 34 2564 (Rest of World)

    International pharmaceutical abstracts

    ProQuest Dialog Pharmaceutical and Biomedical Collection

    Authoritative pharmaceutical and biomedical databases from the world s leading publishers, including Embase, MEDLINE, BIOSIS, Derwent, IMS, Adis and more.

    International pharmaceutical abstracts

    ProQuest Dialog Engineering and SciTech Collection

    Largest multidisciplinary collection of engineering and scitech databases in a single integrated resource, including Ei Compendex, Inspec, SciSearch and ProQuest SciTech and Engineering.

    International pharmaceutical abstracts

    ProQuest Dialog Patents Collection

    The most comprehensive full-text patents offering in the marketplace with 33 full-text and 69 bibliographic patent authorities, plus three patent families Derwent, ProQuest Dialog INPADOC, and LexisNexis Univentio (LNU).

    Benefits

    Multidisciplinary premium content collections

    The authoritative industry sources you expect for pharmaceutical, engineering and patents research, in an interface that adapts to the needs of any user.

    Intuitive access to information for everyone

    Basic, Advanced and Command Line search options for users of every skill level, from the novice searcher to the expert information professional all in one user-friendly interface.

    Sophisticated workflow tools

    Download results, save searches, create custom reports and more, with easy-to-use tools that facilitate collaboration and customization.

    Flexible content and payment packages

    Customized content bundles with flexible pricing plans to meet the needs of every budget, including transactional and subscription packages.

    Unparalleled global customer support

    Our trusted Global Customer Support team is available to support your research needs at every step, including search consultation, Alert set up, technical assistance, and specialized training.

    Database ProSheets

    Sample records and detailed search techniques for the special features of each database on ProQuest Dialog, including description, subject coverage, date range, update frequency, data sources, origin and more. View our ProSheets.





    Pharmaceutical Technology, pharmaceutical industry analysis.#Pharmaceutical #industry #analysis

    pharmaceutical industry analysis

    Pharmaceutical industry analysis

    Pharmaceutical Technology is using cookies

    We use them to give you the best experience. If you continue using our website, we’ll assume that you are happy to receive all cookies on this website.

    Pharmaceutical industry analysis Pharmaceutical industry analysis

    • Log In

    Clinical Trials

    LIFNano: can nanotech ‘flip the switch’ to cure multiple sclerosis?

    Red sage: could this ancient Chinese herb prevent bone loss?

    Nutraceuticals are being held back by regulatory confusion

    Cold Chain

    Evocalcet faces stiff competition in Japan’s CKD-induced hyperparathyroidism market

    Blockchain in pharma: opportunities in the supply chain

    Are drug expiration dates fit for purpose?

    Diseases

    LIFNano: can nanotech ‘flip the switch’ to cure multiple sclerosis?

    Evocalcet faces stiff competition in Japan’s CKD-induced hyperparathyroidism market

    AstraZeneca’s regulatory submission accepted for Tagrisso

    Drug Development

    LIFNano: can nanotech ‘flip the switch’ to cure multiple sclerosis?

    Pharmaceutical M A deals decline

    Pharmaceutical industry analysis

    GSK seeks FDA approval for tafenoquine to treat P. vivax malaria

    Manufacturing

    Boehringer gains EMA approval for Cyltezo, the EU’s third Humira biosimilar

    DIY medicines: the anarchic fringe of the drug price debate

    Can the UK stay on medicine’s cutting edge?

    Market Data

    Evocalcet faces stiff competition in Japan’s CKD-induced hyperparathyroidism market

    Pharmaceutical M A deals decline

    Pharmaceutical industry analysis

    EMA validates BMS’ application to widen cancer therapy indication

    Technology

    DIY medicines: the anarchic fringe of the drug price debate

    Trackable pills: big benefits or Big Brother?

    Inside CARB-X: can this new model for research fix a broken antibiotics market?

    All sections

    LIFNano: can nanotech ‘flip the switch’ to cure multiple sclerosis?

    Cambridge University spin-out company LIFNano is pioneering a new approach to the treatment of multiple sclerosis (MS) by using nanotechnology.

    Red sage: could this ancient Chinese herb prevent bone loss?

    DIY medicines: the anarchic fringe of the drug price debate

    Inside CARB-X: can this new model for research fix a broken antibiotics market?

    NICE’s head of scientific advice on pharma R D in a personalised era

    Pharma Technology Focus – Issue 65

    Boehringer Ingelheim’s Fremont Manufacturing Facility Expansion, California

    Latest News

    Evocalcet faces stiff competition in Japan’s CKD-induced hyperparathyroidism market

    Pharmaceutical M A deals decline

    EMA validates BMS’ application to widen cancer therapy indication

    Get important industry news and analysis sent to your inbox.

    Expert commentary analysis from GlobalData

    Evocalcet faces stiff competition in Japan’s CKD-induced hyperparathyroidism market

    Pharmaceutical M A deals decline

    Boehringer gains EMA approval for Cyltezo, the EU’s third Humira biosimilar

    Shingrix: An effective shingles vaccine with huge commercial promise

    Pharmaceutical industry analysis Top Selling Healthcare Reports

    Most Read

    Company releases

    Medelpharm s Success at AAPS, San Diego

    Hundreds of attendees found their way to the tool in the jungle of formulation at AAPS booth 2003: The STYL’One.

    Single-Use Solutions

    Pharmaceutical industry analysis

    Enterprise Solutions

    Changes in the bioprocessing market demand new ways of thinking. How do you scale up to produce the new treatments.

    GE Healthcare BioPark Biomanufacturing Campus

    Pharmaceutical industry analysis

    Pharmaceutical industry analysis

    Gerresheimer to Showcase Glass and Plastic Pharmaceutical Packaging Products at CPhI

    Gerresheimer has announced it will be showcasing glass and plastic pharmaceutical packaging products that are.

    Company whitepapers

    Meridian 2017 What s New

    Tool for QbD in Tableting

    Unlocking the Potential for Efficiency in Downstream Processing

    High Performance Packaging

    Cadence Acoustic Separator

    Your European Resource for Bioequivalence, Bioavailability, and Phase I Studies

    The Antibody Dependent Cell Mediated Cytotoxicity

    Company A-Z

    Read our magazine

    Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

    Pharmaceutical industry analysis

    Projects

    Boehringer Ingelheim’s Fremont Manufacturing Facility Expansion, California

    Boehringer Ingelheim has broken ground on a $217m expansion of its Fremont facility in California, US.





    Moleculin Biotech – Moleculin Biotech, Inc, biotech company.#Biotech #company

    biotech company

    Biotech company

    Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center, the world’s largest cancer research facility headquartered within the world’s largest medical center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

    Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML.

    Unlike current therapies that risk cardiotoxicity and can have their effectiveness limited due to multidrug resistance, Annamycin appears capable of avoiding both of these problems and has already demonstrated the ability to save lives in clinic. We are now preparing to seek accelerated approval for this game-changing drug.

    We also have two active pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target cell signaling mechanisms and appears capable stimulating the patient’s natural immune system while also attacking tumors directly. The other portfolio targets the metabolism of tumors and exploits a unique approach for crossing the blood brain barrier for the treatment of glioblastoma and other central nervous system malignancies.

    Biotech companyPROBLEM: Cardiotoxicity and multidrug resistance severely limit pediatric oncologists’ ability to effectively treat children suffering from acute leukemia.

    SOLUTION: We believe Annamycin’s ability to avoid both cardiotoxicity and multidrug resistance has the potential to eliminate this critical problem.

    One of the most exciting scientific discoveries here at Moleculin, which we believe will have a profound impact on the treatment of children suffering from Acute Leukemia, is our lead drug Annamycin’s ability to be non-cardiotoxic.

    We believe that this characteristic alone has the ability to change the way pediatric oncologists’ treat children suffering from acute leukemia for the foreseeable future.

    Cardiotoxicity can be a killer, causing severe, permanent and sometimes fatal damage to the heart of both adults and children and cardiotoxicity is highly present in the currently approved drugs used to treat all acute leukemia patients. The drugs that are used to treat acute leukemia patients are called anthracyclines.

    Oncologists (and especially pediatric oncologists) are limited in how they can treat their patients, due to the harmful effects of cardiotoxicity.

    Biotech company

    Here are some quotes from other publications:

    The effectiveness of anthracyclines and related compounds (doxorubicin, daunorubicin, idarubicin, epirubicin, and the anthraquinone mitoxantrone) is hindered by their cardiotoxicity. Cardiotoxicity of anthracycline-like chemotherapy agents

    Anthracyclines remain an important class of drugs in the treatment of cancer, but also remains a problematic chemotherapeutic agent given their cardiotoxic effects. Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment

    To better understand how cardiotoxicity impacts children suffering from acute leukemia, consider that acute leukemia is the most common form of cancer in children, comprising approximately 30 percent of all childhood malignancies. Of the acute leukemias, acute lymphoblastic leukemia (ALL) occurs more commonly than acute myeloid leukemia (AML), however the treatment of both typically involves the same induction therapy (the preparation for a bone marrow transplant) used in adults to reduce the presence of leukemic cells in the patient’s bone marrow and bloodstream in preparation for a curative bone marrow transplant.

    Most unfortunately for children, however, the standard drug used in such induction therapies is significantly cardiotoxic.

    This often means that even though the chances are often good that current treatments can cure a child’s leukemia, it is very likely that the child’s lifespan will be shortened and their quality of life diminished as a result of permanent heart damage caused by current therapies.

    This is why we believe Annamycin’s lack of cardiotoxicity has the ability to change the way children are treated for the foreseeable future.

    Annamycin has been shown to be non-cardiotoxic in animal models, when compared with one of the leading anthracyclines (doxorubicin).

    To make matters worse, the leading induction therapy drugs lose efficacy due to something called “multidrug resistance” requiring more and more drug to try and prepare patients for a successful bone marrow transplant, but because of the harmful effects of cardiotoxicity, patients simply cannot tolerate an increase in dosage. At the same time that Annamycin avoids cardiotoxicity, it also avoids multidrug resistance, and as a result, Annamycin has demonstrated in early clinical trials the ability to deliver efficacy in patients who have failed repeated attempts with the existing induction therapy drugs.

    Oncologists, and especially Pediatric Oncologists, have been clear that there is a tremendous unmet need here and we believe Annamycin has the potential to fill that need and change forever how children with leukemia are treated. The severity of this unmet need may allow us to position Annamycin for accelerated approval under FDA guidelines and we will be working hard this year to secure an accelerated approval pathway. We look forward to moving quickly to translate this important breakthrough into new hope for those children who have run out of options.

    Here are some interesting articles on the effects of cardiotoxicity:

    Cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin’s lymphoma, is a rare cancer that occurs when T-cells in the skin grow uncontrollably. It is estimated that about 16,000 to 20,000 people in the U.S. have CTCL with a higher incidence in men between the ages of 50 and 60 years old.

    CTCL is often mistaken for eczema, psoriasis or contact dermatitis, since it initially presents as patches or plaques. Over time, the patient may develop tumors or generalized erythroderma (abnormal redness of the skin over widespread areas of the body).

    The disease is categorized as Stages I-IV, each of which represents an increased risk for metastasis, or the spread of cancer to distant parts of the body. About three-quarters of the patient population fall into Stages IA, IB and IIA, the lower risk group. Once the disease becomes systemic, however, the prognosis—or outlook—is significantly worse. Beginning with Stage IIB, CTCL is considered progressive (or advanced) and median survival drops to 4 years.

    I have been in drug development for close to 35 years and led the development of carboplatin and cisplatin, which have been blockbuster drugs for years. In all my experience, Annamycin is one of the best drug development opportunities I’ve seen.





    Work with us, Sun Pharmaceutical Industries Ltd, taro pharmaceuticals.#Taro #pharmaceuticals

    Work with us

    Sun Pharma is the fourth largest speciality generic pharmaceutical company in the world. We provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries. It is also India’s largest, most trusted, and most valuable pharmaceuticals company by market capitalisation. Our global revenues are US$ 4.5 billion.

    We attribute our growth and success to our over 30,000 strong multi-cultural workforce from over 50 different nationalities. Our team has taken Sun Pharma to the heights that it has scaled and are now working to take it further up on its high growth trajectory.

    Our people are our most valuable asset. Our culturally diverse workforce is one of our biggest strengths and the rich experience they bring, across varied skill-sets and backgrounds, is invaluable. We are proud that our global workforce is bound together by our common values.

    We are committed to hiring exceptionally talented people and nurture them professionally. Our multi-dimensional work environment offers high growth opportunities through challenging roles with clear responsibilities and the opportunity to work on a variety of assignments. At Sun Pharma, our employees are provided with opportunities to enhance their technical and soft skills through continuous training and development programmes.

    As an employee of Sun Pharma, you will work with an inspiring, approachable and visionary leadership. Our open, enabling and trust-based culture will offer you an exciting environment to work and grow.

    We wish to bring to the notice of all concerned that fake e-mails are being sent in the name of Sun Pharma for job openings with the intention of committing fraud and illegally obtaining money from people. In case you receive any mail for a “Job Opening” or a “Walk-In-Interview” and are asked to deposit money/refundable security amount, purporting to be from Sun Pharma, you are advised not to respond. Sun Pharma never asks for money/refundable security amount to attend any interviews or in connection with any job opening.

    Please check www.sunpharma.com the official website of the company, to get the contact details and enquire with the company to confirm if the purported job opening is genuine. Do not respond to any fraudulent communication and be wary of responding to the bogus text messages that seek data and promise employment.

    We shall not accept any liability towards any representation made in any fraudulent communication or its consequences and such fraudulent communication shall not be treated as any kind of offer or representation by Sun Pharma.





    Home – dsi, kv pharmaceutical.#Kv #pharmaceutical

    Navigation

    Kv pharmaceutical

    Daiichi Sankyo, Inc.

    Theme Search

    Home Page Carousal

    • Kv pharmaceutical
    • Kv pharmaceutical
    • Kv pharmaceutical

    Learn More-HP Updated

    Learn More

    As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability.

    Kv pharmaceutical Commitments in Pain Care

    Daiichi Sankyo is committed to responsibly bringing opioid and non-opioid medicines to the many patients in need of treatment to help alleviate pain.

    Featured News

    Featured News

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Daiichi Sankyo Worldwide

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical

    Kv pharmaceutical





    CGMP Pharmaceutical Stability Studies, pharmaceutical studies.#Pharmaceutical #studies

    cGMP Pharmaceutical Stability Studies

    Pharmaceutical studies

    GMP stability studies and ICH storage supporting pharmaceutical product development, commercial stability studies, batch release and quality control testing

    Stability studies are an essential component of pharmaceutical development, allowing evaluation of active pharmaceutical ingredient (API) stability or drug product stability under the influence of a variety of environmental factors such as temperature, humidity and light. Data from these studies enable recommended storage conditions, retest intervals and shelf lives to be established.

    It is important that you select an experienced stability study outsourcing partner who offers efficient study management, flexible storage conditions and testing capabilities which satisfy all regulatory criteria for your real time, accelerated or forced-degradation study requirements. Stability testing can present significant analytical hurdles, with specialised knowledge required to develop and validate stability indicating methods and perform analysis of leachable substances which migrate from pharmaceutical packaging into the product.

    With a network of ICH stability storage facilities in the UK, US and Australia, we offer an extensive capacity and a range of conditions including climatic walk in chambers, cabinets and refrigerated as well as freezer storage which are fully controlled and monitored with back up chambers at each site. All sites have 24 hour alarm systems with dedicated on call teams to react to the excursions from storage conditions. Our stability teams provide professionally managed Good Manufacturing Practice (cGMP) stability programs for even the most complex of dosage forms, APIs or product types including orally inhaled and nasal drug products (OINDP), biopharmaceuticals, consumer healthcare, medical devices or vaccines. We also offer a responsive and bespoke stability contingency and disaster recovery storage service to help you mitigate the risks associated with costly stability trials.

    GMP Stability Services:

    • cGMP registration stability programs
    • Design, storage and management
    • Development and validation of stability indicating methods
    • Stability testing for APIs, Clinical Trial Materials, formulated products
    • Tailored reporting (timepoint and final reports)
    • All ICH conditions storage
    • Photostability (ICH Q1B Options 1 2)
    • Temperature cycling, freeze-thaw and shipping studies
    • Bespoke or specialised conditions
    • Stability contingency and disaster recovery storage

    Our analytical laboratory network provides development and validation of stability indicating methods through state-of-the-art technology to identify and quantify degradation products. Routine time point testing includes the usual tests such as assay and impurity analysis, dissolution, moisture, hardness, friability and disintegration. Intertek’s scientists have specialist knowledge for OINDP stability testing including measurement of particle or droplet size, providing data critical to understanding the size distribution of the delivered formulation and the delivery of the drug from the device. With unrivalled know-how in extractables and leachables studies, we can ensure that the complete product and packaging system demonstrates sufficient stability and protection over the relevant lifecycle of your product.

    With over 20 years’ experience in stability studies integrated with a comprehensive understanding of the latest developments in regional, country and ICH stability study guidelines we offer a truly flexible stability outsourcing partnership with integrated storage and testing capability which allows you to focus on your core business objectives.





    Seton Hall Law School – Newark NJ, pharmaceutical directory.#Pharmaceutical #directory

    Explore Seton Hall Law

    Additional Resources

    Pharmaceutical directory

    Pharmaceutical directory

    Information

    Financial Aid

    Programs

    Quick Links

    Resources

    Pharmaceutical directory

    Pharmaceutical directory

    News & Directory

    Engagement

    Giving

    Pharmaceutical directory

    • Pharmaceutical directory

    Making a Difference

    through Pro Bono Work

    Kevin McDonough ’05 contributes to final report

    detailing the new role of Rikers Island in

    New York City’s complex criminal justice system

  • Pharmaceutical directory

    On the Rise

    Annual Above the Law

    Top 50 Law School

    Seton Hall Law at #24

  • Pharmaceutical directory

    Two sisters, two different

    Seton Hall Law degrees

    The sisters are both amused and grateful that

    their separate paths converged at Seton Hall law.

    Brooke Emery ’19 (JD) and Leigh Emery ’18 (MSJ)

  • Pharmaceutical directory

    Developing Legal Skills

    Andrew Richman ’16 divides his week between his classes

    at Seton Hall Law and his passion – a legal externship

    in one of the world’s top sports agencies

  • Pharmaceutical directory

    Role Models for Law Students

    Recent elevations of Seton Hall Law alums

    to the New Jersey Superior Court

  • Pharmaceutical directory

    Your view of the City

    Law students with a path to practicing law

    in the largest legal market in the country

  • Pharmaceutical directory

    The Newark Experience

    Students share what it’s like to live, study and work

    in the biggest city in New Jersey

  • Pharmaceutical directory

    Center of Excellence | Health Law

    Surrounded by more than 3,000 health,

    technology and life sciences.

    ADMISSIONS

    STUDENTS

    ABOUT SETON HALL | LAW

    Pharmaceutical directory

    From Opera Stages to Law Classrooms

    From music conservatories to Seton Hall Law School, two first year students graced the stage as opera singers prior to being aspiring lawyers. A Newark native, Caroline Braga is back home after at opera career that began at the ripe age of nine. She went to grade school at Wilson Avenue School, just down the street from where she now studies Contracts and Civil Procedure. Read More





  • Home Page, PhRMA, pharmaceutical directory.#Pharmaceutical #directory

    pharmaceutical directory

    PhRMA represents the country’s leading biopharmaceutical research companies and supports the search for new treatments and cures.

    Advocacy

    From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.

    Science

    Today, cutting-edge medical science is transforming patients’ lives. Discover how scientists and researchers are advancing science.

    Patients

    Patient support and assistance is the top priority for PhRMA’s member companies, who are working hard to improve patients’ lives through the discovery and development of new medicines and treatments.

    Resources

    Explore the Resource Library, the interactive State Map and the Chart Pack reports.

    Search the PhRMA Network

    Stay Connected

    Sign Up for Updates

    Pharmaceutical directory

    Welcome to the future of medicine. Where together, we go boldly.

    Pharmaceutical directory

    PPA strives to improve patient health, advance medical innovation and fuel economic growth.

    Pharmaceutical directory

    The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

    Pharmaceutical directory

    Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

    Pharmaceutical directory

    Learn more about America’s biopharmaceutical companies and how they seek to improve patients’ lives.

    Pharmaceutical directory

    We Work For Health aims to increase awareness by uniting workers throughout the industry.

    Pharmaceutical directory

    Patent protection should always be considered by an inventor during the initial stages of their invention.

    Pharmaceutical directory

    Working to spread awareness and education about the importance of secure drug disposal.





    It – s Here: the 2017 Pharma Sales Salary Report, pharmaceutical sales companies.#Pharmaceutical #sales #companies

    2017 Pharmaceutical Sales Salary Report

    Request a monthly email with our latest articles and reports.

    Pharmaceutical sales companies

    Pharma and pharma specialty sales reps are knocking it out of the park, according to our 2017 Pharmaceutical Sales Salary Report. This year the average pharmaceutical sales salary is $128,489 (Median Total $125,500). While these are impressive numbers, specialty pharma reps continue earning significantly more. The average specialty pharma sales salary is $147,318 (Median Total $145,500). Pharmaceutical sales companies

    Thanks to their diligence and hard work, pharmaceutical reps continue pushing their salaries up the chart. And due to a strong passion for the industry, pharma sales remains a highly sought after career.

    Even though pharma reps earn the lowest average incomes compared to other product categories with specialty reps in the bottom four many pharma reps report having very successful, satisfying careers.

    About the Survey

    One-fourth of this year’s survey respondents (666) noted that they sold Pharmaceutical or Specialty Pharmaceutical products. The average total income for the overall group was $136,481.

    In addition to income, the survey asked respondents about their job titles, target customer base, the type and size of their companies and more. Even factors such as gender, age, and ethnicity appear to have some correlation with pharma salaries.

    Pharmaceutical sales companies

    Average Pharma Sales by Job Title and Company Size

    Climbing the pharma sales ladder will help you reach the highest available salaries. While income is important, remember to look at your final goal in relation to your skills and passions. Where do you want to go with your pharma sales career?

    Pharmaceutical sales companies

    Pharmaceutical sales companies

    Pharma Sales Salary by Age and Experience

    Pharma sales is a challenging business, so it’s no surprise that salary increases come with both age and experience. The biggest jump we noticed this year is from age 30 to age 40, suggesting pharma reps must pay their dues and gain experience before earning top dollar.

    Pharmaceutical sales companies

    Gender and Ethnicity in Pharma Sales

    In a perfect world, we would no longer need to write about the roles of gender and ethnicity in the workplace. Unfortunately, they still have an effect on many industries including pharma sales.

    While the movies often portray pharma sales reps as beautiful women rolling a suitcase into doctors’ offices, the image is a large misrepresentation. In fact, only 31 percent of pharma sales reps are women.

    Pharmaceutical sales companies

    What’s even more surprising is that, of our respondents, Black/African Americans only represent 7 percent of pharma sales employees, and Hispanics a mere 6 percent.

    Pharmaceutical sales companies

    Pharma Sales Travel and Location

    Professionals who spend 50 percent or more of their time traveling for pharmaceutical sales jobs earn significantly more money than those who travel less or not at all. Professionals traveling 75 percent of the time earn the most.

    Pharmaceutical sales companies

    However, where these respondents live also has an impact on earning potential. Take a look at your possibilities:

    Pharmaceutical sales companies

    Year Over Year Pharma Sales Income

    While pharma sales isn’t the highest paid medical sales field, the future looks promising. Each year, successful, ambitious reps are driving the total compensation numbers up.

    Pharmaceutical sales companies

    Conclusion

    When discovering your medical sales dreams and career goals, don’t be discouraged by the fact that pharma sales salaries are on the lower end of the spectrum. The figures remain impressive and are continually growing, so the future s looking brighter than ever.

    In addition to your salary, medical sales companies offer valuable perks. In our medical sales survey, 87 percent of reps reported having health benefits, 80 percent have 401k with employer matching, and 74 percent reap the rewards of an expense account.

    With a solid income and plenty of perks, it’s easy to see why pharma sales jobs continue to be highly sought-after among medical sales jobs.

    Pharmaceutical sales companies





    Oral Solid Dosage Pharmaceutical Formulation Market – Global Industry Analysis, Size and Forecast, 2017 to

    Oral Solid Dosage Pharmaceutical Formulation Market Segmentation By Dosage Form – Tablets, Capsules, Powders, Others; By Drug Release Mechanism – Immediate Release, Extended Release (Sustained Release, Controlled Release), Others; By Distribution Channel – Hospital Pharmacy, Retail Pharmacy, Drug Stores, Online Pharmacy

    Pharmaceutical industry analysis

    Oral Solid Dosage Pharmaceutical Formulation Market: Emerging Markets of Latin America, APEJ and MEA to Collectively Hold over 45% Market Value Share: Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027

    • REP-GB-2782
    • 2017-07-18
    • 195 Pages
    • Format:Pharmaceutical industry analysisPharmaceutical industry analysis
    • Category:Healthcare, Pharmaceuticals and Medical devices

    Future Market Insights forecasts the global oral solid dosage pharmaceutical formulation market to grow from US$ 493.2 Bn in 2017 to US$ 926.3 Bn by 2027 end. This represents a value CAGR of 6.5% over the forecast period 2017 2027. Several important factors drive this growth. We present these factors in detail in our report. A snapshot is captured below for our readers benefit.

    Growth Factor : Most promising yet cost-effective dosage form

    Oral solid dosage forms are the most commonly used pharmaceuticals to treat various disease conditions. Oral solid dosage forms are cost-effective and easy to manufacture in comparison with other dosage forms. They offer significant benefits to manufacturers such as trouble free packaging and transportation and increased chemical and physical stability. Oral solids offer many advantages to patients as well. For instance, oral solid dosage forms are often chosen by patients owing to the inherent advantages in dosage administration and no necessity of dose measurement. They can be formulated in different flavours and in different dosage forms in order to increase patient compliance. For instance, few APIs have unpleasant taste, and in order to avoid this, they are manufactured in the form of effervescent tablets to achieve patient acceptability and compliance. Recent advances in drug delivery are enabling oral solid dosage manufacturers to achieve significant bioavailability by adopting novel drug delivery technology platforms. For example, targeted drug delivery and sustained release of dosage forms in oral solid dosage formulations enhance the bioavailability of the drugs and reduce the frequent administration of drugs, thereby contributing to significant growth of oral solid dosage forms.

    Growth Factor : Growth in APEJ region driven by rise in affluent consumers and super generics

    Huge boost in the APEJ market for oral solid dosage pharmaceutical formulations is coming from a sharp rise in new affluent consumers in countries such as India, China and Korea. Both multinational companies as well as local drug manufacturers are benefiting from the rapidly growing population of India and China. This group of affluent consumers is adopting a wealthy and fast-paced western lifestyle and thus have begun to suffer with western lifestyle related diseases such as diabetes, cancer and obesity, for which they seek and can afford innovative drug treatments. Moreover, generic manufacturers have entered into the production of super-generics i.e., modified versions of approved off-patent small-molecule drugs that offer a therapeutic advantage and thus distinguish them from me-too generic drugs. For instance, Ranbaxy Laboratories Ltd. India based manufacturer of generic medicine has developed once-a day Ciprofloxacin tablet, a super generic antibiotic. The company licensed it to Bayer and opened up an opportunity in the global market.

    Global Oral Solid Dosage Pharmaceutical Formulation Market Attractiveness Analysis, By Region

    North America dominated the global oral solid dosage pharmaceutical formulation market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. North America is expected to be the most lucrative among all regions, with a market attractiveness index of 2.7. Consolidation of the pharmaceutical industry in the U.S. combined with an expansion in outsourcing is boosting revenue growth of the oral solid dosage pharmaceutical formulation market in the region. APEJ is expected to be the second most lucrative market for oral solid dosage pharmaceuticals, with a market attractiveness index of 2.6. APEJ remains the third largest market due to rapidly increasing penetration of generics in China and India. MEA is expected to remain the least attractive regional market in terms of revenue, with a market attractiveness index of 0.1 over the forecast period.

    Pharmaceutical industry analysis

    Every market is challenged by certain factors that tend to hamper overall growth. We have focussed on these growth limiters in detail in our report. One such factor restraining market growth is highlighted below.

    Diminishing share of oral solids in the development pipeline

    Growing research on biologics molecules and their dominance in treating oncology conditions are hampering the growth of the oral solid dosage pharmaceutical formulation market. Furthermore, investments by government organisations to conduct research activities in biologics coupled with an increase in biotech start-ups have had a negative impact on oral solid dosage forms. According to an article published in Contract Pharma, approximately 50% of the pipeline molecules are biologics and the rest in the form of other dosage forms. Companies are betting heavily on biologics owing to their high returns in terms of value. For instance, in 2016, the top 10 drugs generated around US$ 79 Bn in terms of value; among these, 76.8% were from biologics.

    In this report, historical data, primary responses and public domain data has been thoroughly analysed to infer the market size. Revenue of companies operating in the oral solid dosage pharmaceutical formulation market has been benchmarked to ascertain the market size for the base year. Macroeconomic indicators such as GDP and industry growth have been considered to determine the market size for the forecast period. The historical growth trend of end-use industries, market participants performance, as well as the present macro-economic outlook has been taken into consideration for estimating the overall market trend forecast. This data is then validated using the triangulation method and is extensively scrutinised using advanced tools to garner quantitative and qualitative insights into the global oral solid dosage pharmaceutical formulation market.

    By Drug Release Mechanism





    Saudi Pharmaceutical Journal, pharmaceutical directory.#Pharmaceutical #directory

    Saudi Pharmaceutical Journal

    Enter your login details below. If you do not already have an account you will need to register here.

    Useful links

    Track accepted paper

    Once production of your article has started, you can track the status of your article via Track Your Accepted Article.

    • CiteScore: 2.63 ℹ CiteScore measures the average citations received per document published in this title. CiteScore values are based on citation counts in a given year (e.g. 2015) to documents published in three previous calendar years (e.g. 2012 – 14), divided by the number of documents in these three previous years (e.g. 2012 – 14).
    • More about CiteScore
    • Impact Factor: 2.302Impact Factor:

    The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

    2016 Journal Citation Reports (Clarivate Analytics, 2017)

  • 5-Year Impact Factor: 2.611Five-Year Impact Factor:

    To calculate the five year Impact Factor, citations are counted in 2016 to the previous five years and divided by the source items published in the previous five years.

    • Author Stats ℹ Author Stats:

    Publishing your article with us has many benefits, such as having access to a personal dashboard: citation and usage data on your publications in one place. This free service is available to anyone who has published and whose publication is in Scopus.

  • Publishing Campus
  • Author Services
  • Peer Review under the responsibility of King Saud University

    The Saudi Pharmaceutical Journal (SPJ) is the official journal of the Saudi Pharmaceutical Society (SPS) publishing high quality clinically oriented submissions which encompass the various disciplines of pharmaceutical sciences and related subjects. SPJ publishes 8 issues per year by the Saudi Pharmaceutical.

    The Saudi Pharmaceutical Journal (SPJ) is the official journal of the Saudi Pharmaceutical Society (SPS) publishing high quality clinically oriented submissions which encompass the various disciplines of pharmaceutical sciences and related subjects. SPJ publishes 8 issues per year by the Saudi Pharmaceutical Society, with the cooperation of the College of Pharmacy, King Saud University.

    All articles published in Saudi Pharmaceutical Journal have undergone a full peer review and are:

    • Scientifically sound
    • In compliance with international research and publishing ethics
    • Written in clear, concise and correct English
    • A valid, contribution to the existing literature and of educational value to the specific community and readers
    • Not previously published material

    The journal publishes full-length articles, short reviews (not exceeding 12 pages which are intended to debate the recent advances in rapidly developing fields), short communications, case studies, letters to the editor and book reviews.

    Medicinal chemists, Pharmacologists, Pharmacists, Toxicologists, Clinicians and all other health practitioners.

    Medicinal chemistry, structure based drug design, drug target, industrial pharmacy, medicinal research, drug targeting, enzyme inhibitors, receptor, pharmaceutical chemistry, drug delivery, drug discovery, biological chemistry, drug development, pharmaceutical technology, and pharmaceutical biotechnology.

    Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://service.elsevier.com

    Accredited as a refereed Journal by the Scientific Council of King Saud University, Riyadh, Kingdom of Saudi Arabia.